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6ABBREVIATIONS
AA arachidonic acid
ACF aberrant crypt foci
Apc adenomatous polyposis gene
cDNA complementary deoxyribonucleic acid
COX cyclooxygenase
DDFS distant disease-free survival
DCIS ductal carcinoma in situ
DMBA 7,12-dimethylbenz(a)anthracene
ER estrogen receptor
FAP familial adenomatous polyposis
IL interleukin
Min multiple intestinal neoplasia
mRNA messenger ribonucleic acid
MMP matrix metalloproteinase
NSAID nonsteroidal anti-inflammatory drug
PG prostaglandin (e.g., PGD2, PGE2, PGF2α, PGG2, PGH2, PGI2)
PR progesterone receptor
PhIP 2-amino-1-methyl-6-phenylimid-azo[4,5-b]pyridine
PLA2 phospholipase A2
PPAR peroxisome proliferator-activated receptor
RT-PCR reverse transcriptase polymerase chain reaction
TNF tumor necrosis factor
VEGF vascular endothelial growth factor
7ABSTRACT
Epidemiological studies indicate that use of nonsteroidal anti-inflammatory drugs
(NSAIDs) is associated with reduced risk for cancer of the digestive tract including
esophageal carcinoma. Association of NSAID use with incidence of non-
gastrointestinal malignancies is less clear, but a recent report showed that regular
use of aspirin reduced risk for breast cancer especially in hormone receptor-
positive patients. The best-known target of NSAIDs is the cyclooxygenase (COX)
enzyme. Two isoforms of COX are known. COX-1 is expressed in a constitutive
manner, with its role connected to physiological functions such as cytoprotection
of the stomach and control of platelet aggregation. In contrast, expression of COX-
2 is undetectable in most healthy tissues, but can be induced in response to cell
activation by proinflammatory cytokines, growth factors, and tumor promoters,
and its role has been connected to inflammation and carcinogenesis.
Functionally, COX-2-derived prostanoids inhibit apoptosis, promote angiogenesis,
induce invasion, and increase metastasis. Genetic deletion of COX-2 in mouse
models of familial adenomatous polyposis (FAP) leads to a reduced polyp burden,
and in a transgenic mouse model, overexpression of COX-2 is sufficient to
promote mammary gland tumorigenesis. In addition, two different selective COX-
2 inhibitors have reduced polyp burden in patients with FAP. In breast and
esophageal cancer patients, expression of COX-2 is elevated, but the clinical
relevance of this finding is yet unknown.
The purpose of this study was to investigate whether expression of COX-2 is
associated with clinicopathological parameters and clinical outcome in human
breast and esophageal cancer patients. In breast cancer specimens, we also
investigated the correlation of COX-2 expression with HER-2, estrogen receptor
(ER), progesterone receptor (PR), p53, and matrix metalloproteinase-2 (MMP-2). In
respect to esophageal cancer, we evaluated COX-2 protein expression and
prognostic significance in two different histological types of esophageal
carcinoma: adenocarcinoma and squamous cell carcinoma. In addition, we
investigated whether the prognostic significance of COX-2 depends on patients’
preoperative chemotherapy.
8Our results show that expression of COX-2 protein was associated with decreased
survival in two independent cohorts of breast cancer patients. Interestingly, our
data indicate that the prognostic value of COX-2 expression tended to be more
marked in certain subgroups of patients, e.g., those with estrogen receptor positive
tumors. Thus, the tumor-promoting effect of COX-2 may not be evenly distributed
throughout a breast cancer cohort, and certain subgroups of patients may benefit
more from COX-2-targeted therapy. In order to understand the carcinogenic
mechanism of COX-2 in human malignancies, we correlated its expression with
expression of MMP-2, known to promote cancer cell invasion and metastasis. Our
data show that expression of COX-2 was associated with MMP-2 expression in
breast carcinoma specimens. This suggests that COX-2-derived prostanoids may
induce expression of MMP-2 in human tumors, which has previously been shown
in experimental cancer models.
Our study was the first to report that in adenocarcinoma of the esophagus, high
expression of COX-2 is associated with reduced survival. In contrast, in
esophageal squamous cell carcinoma, COX-2 expression was not associated with
patient outcome. Low COX-2 expression was, however, associated with poor
prognosis in patients with esophageal squamous cell carcinomas who received
neoadjuvant chemotherapy. Taken together, our results suggest that the prognostic
significance of COX-2 differs depending on the histological type of esophageal
carcinoma and on the treatment applied.
9REVIEW OF THE LITERATURE
COX and cancer
COX-1 and COX-2 enzymes
For thousands of years, one treatment for pain has been willow bark. Its active
constituent was found to be salicylate, and its better-tolerated derivate
acetylsalicylate was introduced as aspirin by the middle of the nineteenth century.
In 1971 its mechanism of action was discovered when Vane found that aspirin
blocks the production of prostaglandins (PG) (Vane, 1971). Vane and two Swedish
scientists, Bergström and Samuelsson, won the Nobel Prize in Physiology and
Medicine for that discovery in 1982. COX enzyme, now known as COX-1, was
first characterized from bull vesicular glands in 1976 (Miyamoto et al., 1976).
Three groups cloned COX-1 cDNA from sheep seminal vesicles in 1988 (DeWitt
and Smith, 1988; Merlie et al., 1988; Yokoyama et al., 1988), followed by cloning
of human cDNA from the platelets in 1991 (Funk et al., 1991). It soon became
evident that there might exist several isoforms of the COX enzyme: constitutive
and inducible. In 1991, two independent groups reported simultaneously an
inducible COX enzyme called COX-2 (Kujubu et al., 1991; Xie et al., 1991), and
in 1992, human COX-2 cDNA was cloned from human umbilical vein
endothelial cells (Hla and Neilson, 1992).
COX-1 is expressed constitutively in most tissues and cells except red blood cells.
It is believed to be primarily a housekeeping gene responsible for synthesis of the
PGs that control normal physiological functions such as maintenance of the
gastric mucosa, platelet aggregation, and regulation of renal blood flow. On the
other hand, COX-2 is an inducible immediate-early response gene undetectable
in most normal tissues but induced by various cytokines, growth factors,
hormones, and tumor promoters (Herschman, 1996). At cellular level, both COX
enzymes are expressed in the endoplasmic reticulum and nuclear envelope
(Morita et al., 1995; Spencer et al., 1998) (Table 1). A new COX variant recently
identified and designated COX-3 has the same structure as COX-1, except that its
mRNA has retained intron-1, which is also translated into a 30-amino acid
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extension to the protein (Chandrasekharan et al., 2002). Thus, it is a splicing
variant of COX-1 (Chandrasekharan and Simmons, 2004).
Table 1: Properties of human COX-1 and COX-2 genes and gene products.
Property COX-1 COX-2
Chromosomal location Chromosome 9 Chromosome 1
Gene size 22 kb 8.3 kb
Number of exons 11 10
Number of introns 10 9
mRNA size 2.7 kb 4.5 kb
Regulation Constitutive Inducible
Molecular weight 72 kDa 72 kDa
Subcellular location Endoplasmic reticulum
and nuclear envelope
Endoplasmic reticulum
and nuclear envelope
COX enzymes, which catalyze the rate-limiting step in PG synthesis, the
conversion of arachidonic acid (AA) (a 20-carbon polyunsaturated fatty acid) to
PGH2, consist of three domains: an epidermal growth factor domain, a
membrane-binding motif, and an enzymatic domain containing both COX and
peroxidase activity sites (Luong et al., 1996). The first step in PG synthesis is
mobilization of AA from membrane phospholipids in a reaction catalyzed by the
phospholipase A2 (PLA2) family of enzymes. The next step is catalyzed by COX,
which inserts molecular oxygen into AA. This reaction produces an unstable
product, PGG2, which is rapidly converted by COX peroxidase activity to PGH2.
Specific synthases then convert PGH2 to various prostanoids, including PGD2,
PGE2, PGF2α, PGI2, and TXA2, each prostanoid having its own range of biological
activities. Different PGs are synthesized in a broad range of tissue types and act as
autocrine or paracrine mediators to signal changes within the immediate
environment (Simmons et al., 2004). PGs act through binding to transmembrane,
G-protein-coupled cell-surface receptors that act through changes in cellular
levels of cyclic AMP and Ca+. In addition, PGs can act directly within the nucleus
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through nuclear peroxisome proliferator-activated receptors (PPARs) (Simmons et
al., 2004).
Table 2: COX-2 expression in carcinoma.
Adenocarcinoma
Colorectal Eberhart et al., 1994
Breast Parrett et al., 1997
Stomach Ristimäki et al., 1997
Esophagus Wilson et al., 1998
Lung Huang et al., 1998b
Liver Shiota et al., 1999
Pancreas Tucker et al., 1999
Cervix Ryu et al., 2000
Endometrial Tong et al., 2000
Prostate Gupta et al., 2000
Ovarian Matsumoto et al., 2001
Thyroid Specht et al., 2002
Squamous cell carcinoma
Lung Huang et al., 1998b
Skin Buckman et al., 1998
Esophagus Zimmermann et al., 1999
Head & neck Chan et al., 1999
COX-2 expression in cancer
While COX-2 expression is undetectable in most normal tissues, it is
overexpressed in several different types of carcinoma. Eberhart et al. (1994) were
the first to document elevated expression of COX-2 in human colorectal
carcinoma and adenoma. Other studies have confirmed that COX-2 mRNA and
protein are elevated in 75 to 100% of human colorectal cancers (Kargman et al.,
1995; Sano et al., 1995; Kutchera et al., 1996). Similar to colorectal cancer, COX-
2 is expressed in several other types of carcinomas, including breast and
esophagus (Table 2). COX-1 expression can be detected in most tissues and cells
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except red blood cells. In contrast to COX-2, the level of COX-1 expression is not
usually elevated in malignant tissues when compared to levels in nonneoplastic
tissue of the same organ (Dubois et al., 1998).
NSAIDs and cancer
One of the first clues that COX inhibition might be an effective means to prevent
cancer came from epidemiological studies. Epidemiological data indicate that risk
for colorectal cancer is reduced by approximately half in those regularly taking
aspirin or other NSAIDs (Thun et al., 1991; Thun et al., 1993; Giovannucci et al.,
1994; Giovannucci et al., 1995). Since NSAIDs are known to inhibit COX enzyme
activity, elevated prostaglandin levels may contribute to development of
colorectal cancer. In addition, epidemiological data suggest that NSAIDs may also
reduce risk for cancers in the stomach (Langman et al., 2000), esophagus (Table
3), and breast (Khuder and Mutgi, 2001; Terry et al., 2004).
Gastrointestinal side-effects of NSAIDs such as ulceration, bleeding, and
perforation are presumably mediated via inhibition of COX-1. Therefore, selective
COX-2 inhibitors were created to avoid NSAID-related gastrointestinal side-
effects. That the substrate-binding site of COX-2 is larger and has a slightly
different shape than that of COX-1 allows selective COX-2 inhibitors to bind in
this additional space (Luong et al., 1996). Long-term use of selective COX-2
inhibitors has now been tested in several large randomized trials (Langman et al.,
1999; Simon et al., 1999; Silverstein et al., 2000), confirming their improved
gastrointestinal safety profile compared to that of non-selective COX-2 inhibitors.
Concern has, however, been raised as to the possible cardiovascular risk
associated with these new drugs (Mukherjee et al., 2001). Indeed, it was reported
recently that three different COX-2 inhibitors: rofecoxib, celecoxib, and
valdecoxib all increased cardiovascular toxicity in three large, randomized,
controlled trials (Bresalier et al., 2005; Nussmeier et al., 2005; Solomon et al.,
2005)
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Table 3: Retrospective studies on the protective effect of NSAIDs for esophageal
adenocarcinoma.
Reference Method Sample Outcome NSAIDs
results
Thun et al.,
1993
Epidemiologic
study
Follow-up
n = 635 031 Death rates RR = 0.59
95% CI =
0.34-1.03
Funkhouser
and Sharp,
1995
Epidemiologic
study
Follow-up
n = 14 407 Esophageal
cancer
incidence
RR = 0.10
95% CI =
0.01-0.76
Farrow et
al., 1998
Case control
Population-
based
Cases: 650
Controls: 695
Esophageal
cancer
incidence
OR = 0.37
95% CI =
0.24-0.58
Langman et
al., 2000
Case control
Population-
based
Cases: 12 174
Controls:
34 934
Esophageal
cancer
incidence
OR = 0.64
95% CI =
0.41-0.98
Coogan et
al., 2000
Case control
Hospital based
Cases: 1 149
Controls: 5 952
Esophageal
cancer
incidence
OR = 0.8
95% CI =
0.5-1.4
RR = relative risk; CI = Confidence Interval; OR = Odds Ratio.
In addition to inhibiting tumor growth via COX inhibition, NSAIDs can act
through COX-independent mechanisms, e.g., by antagonizing the NF-κB signaling
pathway (Kopp and Ghosh, 1994), by reducing levels of the antiapoptotic protein
Bcl-XL (Zhang et al., 2000), or through PPARs (Lehmann et al., 1997; He et al.,
1999). However, concentrations of the drugs required to affect these pathways are
relatively high; at pharmacological doses, COX enzymes are the best-
characterized targets of NSAIDs (Gupta and Dubois, 2001).
Animal studies
The association between COX-2 and tumorigenesis has been evaluated in various
rodent models. In an azoxymethane-induced rat model of colon carcinogenesis,
animals develop pre-neoplastic colonic lesions called aberrant crypt foci (ACF),
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which later progress into carcinomas. Aspirin and the COX-2 selective inhibitor
celecoxib reduced ACF formation and multiplicity (Reddy et al., 1993; Kawamori
et al., 1998; Reddy et al., 2000). In a nude mouse xenograft model, both the non-
selective COX-inhibitor meloxicam (Goldman et al., 1998) and the selective COX-
2 inhibitors celecoxib and SC-58125 (Sheng et al., 1997; Williams et al., 2000b)
reduced colon carcinoma growth. In addition, SC-58125 could reduce tumor
formation in nude mice in a COX-2-expressing cell line, whereas no effect
appeared with a non-COX-2-expressing cell line (Sheng et al., 1997).  Min mice
(Su et al., 1992) and ApcΔ716 mice (Oshima et al., 1995) develop multiple
adenomas predominantly in the small intestine (Bilger et al., 1996). Both non-
selective NSAIDs and selective COX-2 inhibitors can reduce polyp formation in
these mice (Boolbol et al., 1996; Oshima et al., 2001). In addition to prevention
studies, COX-2 inhibitors are also being evaluated as therapeutic agents for pre-
existing tumors; Celecoxib reduces tumor multiplicity in Min mice when
administered after adenomas have been established (Jacoby et al., 2000).
More strikingly, genetic disruption of COX-2 inhibits polyp size and number in
ApcΔ716-knockout mice, and the polyp number fell by 66% in Cox-2+/- mice and
86% in Cox-2-/- mice, making the effect gene-dose dependent (Oshima et al.,
1996). This provides direct genetic evidence that COX-2 plays a role in intestinal
polyp formation. However, one study showed an equivalent reduction in tumor
multiplicity in Min mice that were null for either Cox-1 or Cox-2 (Chulada et al.,
2000). A study by Liu et al. (2001) was the first to show that overexpression of
COX-2 alone is sufficient to induce cellular transformation. They created a
transgenic mouse that expresses the human COX-2 gene under the MMTV
promoter, which directs the expression in the mammary glands. These mice, after
multiple pregnancies, develop mammary gland hyperplasias, dysplasias, and
metastatic tumors.
Clinical evidence
Familial adenomatous polyposis (FAP) is an autosomal dominant inherited
disease, in which patients develop numerous adenomatous polyps in the colon
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that predispose to colorectal carcinoma. The genetic mutation responsible for this
disease is a germline mutation of the APC gene. Somatic mutations in the APC
gene occur also in a large number of sporadic colorectal cancers. A randomized,
double blind, placebo-controlled clinical trial showed that sulindac, a non-
selective COX inhibitor, can reduce size and number of colonic polyps in FAP
patients (Giardiello et al., 2002). In addition, recently two different selective COX-
2 inhibitors reduced polyp burden in patients with FAP. In a randomized, double-
blind, placebo-controlled study with 77 FAP patients, Steinbach et al. (2000)
showed that treatment twice daily with 400 mg celecoxib caused a 28%
reduction in the number of colorectal polyps compared with a 4.5% reduction for
placebo. Polyp burden was also reduced in the celecoxib group. Higuchi et al.
(2003) obtained similar results with another selective COX-2 inhibitor, rofecoxib.
The promising results of these FAP studies have led to several ongoing clinical
trials of selective COX-2 inhibitors (Anderson et al., 2002).
Role of COX-2 in tumorigenesis
During tumorigenesis, increased COX-2 expression is likely to be a consequence
of multiple effects. For example, transcriptional activation can occur in response
to growth factors and oncogenes. Several oncogenes that can upregulate COX-2
expression include v-src, v-Ha-ras, HER-2, and Wnt genes (Howe et al., 2001).
COX-2 expression can also be controlled by regulating COX-2 mRNA stability
(Ristimäki et al., 1994; Dixon et al., 2000). The COX-2 product PGE2 is thought to
be responsible for the cancer-promoting effects of COX-2. A recent study
demonstrated that PGE2 could mediate its action by transactivation of epidermal
growth factor receptor in gastric epithelial cells, colon cancer cells, and in rat
gastric mucosa (Pai et al., 2002). Furthermore, mice lacking the PGE2 receptor
subtypes EP1 or EP4 showed a decreased formation of chemically induced ACF
(Watanabe et al., 1999; Mutoh et al., 2002), and genetic disruption of the EP2
receptor reduced the number and size of intestinal polyps in ApcΔ716 mice
(Sonoshita et al., 2001). Synthesis of PGE2 seems to be mechanistically linked to
formation of neoplasias by its inhibiting apoptosis, promoting angiogenesis,
inducing metastasis and invasion, and inducing immunosuppression (Figure 1).
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Figure 1: Putative roles of COX-2 in carcinogenesis.
Tumor growth depends on a balance between cell proliferation and apoptosis
(Hanahan and Weinberg, 2000). Several studies demonstrate a connection
between apoptotic response and COX-2 expression. Overexpression of COX-2 in
rat intestinal epithelial cells has elevated amounts of the anti-apoptotic Bcl-2
protein and led to resistance to butyrate-stimulated apoptosis (Tsujii and DuBois,
1995). In colorectal cancer cells, PGE2 can upregulate Bcl-2 protein and suppress
apoptosis induced by a selective COX-2 inhibitor (Sheng et al., 1998). Celecoxib
can induce apoptosis in human prostate cancer cells (Hsu et al., 2000), and the
COX-2 inhibitior NS-398 can induce apoptosis through a cytochrome c-
dependent pathway in esophageal cancer cells (Li et al., 2001a). In COX-2
transgenic mice, the tumor tissue expresses reduced levels of the proapoptotic
proteins Bax and Bcl-xL. In addition, mammary gland involution is delayed, with a
decrease in the apoptotic index of mammary epithelial cells. Alternatively, since
AA stimulates cells to undergo apoptosis, enhanced COX-2 expression, by
increasing the conversion of AA to PGs, can inhibit apoptosis (Cao et al., 2000).
COX-2 can also promote tumorigenesis through direct action on the stromal
compartment by stimulating development of tumor-associated angiogenesis. This
is an important step in tumorigenesis, since neovascularisation is necessary for
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tumors to grow beyond 3 mm in size (Folkman, 2002). Overexpression of COX-2
in colon cancer cells raises the production of angiogenic factors and formation of
capillary-like networks; the selective COX-2 inhibitor NS-398 can inhibit these
effects (Tsujii et al., 1998). Recently, a study showed that PGE2 and PGI2 have an
essential function in endothelial cell spreading and migration mediated by the
integrin αVβ3 (Dormond et al., 2001). In addition, COX-2-overexpressing cells
can up-regulate vascular endothelial growth factor (VEGF)-C and
lymphangiogenesis in human lung adenocarcinoma cells (Su et al., 2004). In vivo,
corneal blood vessel formation is suppressed by celecoxib, but not by the COX-1
inhibitor SC-560, in a rat model of angiogenesis (Masferrer et al., 2000).
Interestingly, host COX-2 is important in tumor neovascularization, because Lewis
lung carcinoma xenocrafts, implanted in COX-2 knockout mice, showed
reduction in growth and vascular density when compared to tumors implanted in
wild-type mice. Consistently, COX-2-null fibroblasts showed reduced ability to
produce VEGF compared to that of the wild-type (Williams et al., 2000a). Indeed,
COX-2 expression is not restricted to the epithelial component of the human
tumor, since endothelial cells of the angiogenic vasculature in human colon,
breast, prostate, and lung cancer biopsy tissues also expresses COX-2 (Masferrer
et al., 2000). In addition, in human breast tumors, COX-2 expression correlates
with staining of CD31, an endothelial cell marker of angiogenesis (Davies et al.,
2003).
COX-2 has been shown to induce invasion and metastasis. In a Matrigel invasion
assay, overexpression of COX-2 in colorectal cancer cells can enhance
invasiveness and induce expression or activity of several enzymes capable of
digesting the basement membrane (Tsujii et al., 1997). In non-small cell lung
carcinoma cells, stable overexpression of COX-2 induced invasiveness of the cells
(Dohadwala et al., 2002), and in prostate cancer cells, the COX-2 selective
inhibitor NS-398 suppressed invasiveness (Attiga et al., 2000). In addition, adding
PGE2 to colorectal cancer cells leads to an increase in cell proliferation and
motility associated with activation of the PI3K/AKT pathway (Sheng et al., 2001).
In animal models, selective blockade of COX-2 suppresses metastasis. The COX-2
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selective inhibitor JTE-522 reduced the amount of lung metastasis in mice injected
with COX-2-overexpressing colorectal cancer cells, but this was not the case with
low COX-2-expressing cells (Tomozawa et al., 1999). In addition, a recent study
showed that the COX-2 selective inhibitor rofecoxib could reduce metastasis in a
mouse model of colorectal carcinogenesis (Yao et al., 2003).
COX-2 or PGs can regulate host immune surveillance. PG-mediated
immunosuppression may contribute to tumorigenesis, since it allows tumors to
avoid immune surveillance that would otherwise limit cancer growth. This was
evident in a murine lung tumor model where inhibition of COX-2 altered the
balance between interleukin (IL)-10 and IL-12 (Stolina et al., 2000). In addition,
PGE2 can inhibit production of tumor necrosis factor (TNF)α while inducing IL-10
production (Huang et al., 1998a).
In addition to its PG-mediated contribution to tumorigenesis, COX-2
overexpression may have PG-independent consequences. COX-2 overexpression
may result in increased production of mutagens. Peroxidase activity of COX-2
catalyzes the conversion of procarcinogens, such as benzo[a]pyrene, to
carcinogens. This activity is especially important in organs exposed to tobacco
carcinogens (Wiese et al., 2001). COX-2 can also be induced by procarcinogens
present in such substances as tobacco smoke and grilled foods (Kelley et al.,
1997). Furthermore, by-products of the oxidation of AA such as malondialdehyde
are highly reactive and form adducts with DNA (Plastaras et al., 2000).
Prognostic role of COX-2 in digestive tract carcinomas
Sheehan et al. (1999) were the first to show that expression of COX-2 is associated
with tumor aggressiveness. They showed in 76 colorectal cancer patients that
extent of COX-2 staining correlated with lymph node involvement, large tumor
size, more advanced Dukes stage, and a poorer prognosis. In a more recent study
in 100 colon cancer patients, COX-2 protein expression correlated with
unfavorable pathological variables, microvessel density, and shorter survival time
(Masunaga et al., 2000). Neither of these studies demonstrated COX-2 as an
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independent prognostic factor. In another study, in 63 colon cancer patients,
COX-2 protein overexpression was related to degree of metastasis and local
recurrence (Tomozawa et al., 2000). In contrast, no correlation appeared between
COX-2 expression and survival in 139 colorectal cancer patients (Wu et al.,
2003). In gastric cancer, COX-2 protein expression was associated with poor
prognosis in 71 gastric cancer adenocarcinoma specimens (Chen et al., 2001). In
contrast, a study on 104 human gastric carcinoma samples found no association
between COX-2 protein expression and patient survival (Lim et al., 2000). In
squamous cell carcinoma of the oral cavity, COX-2 overexpression both at the
time of surgery and in recurrences associated with lymph node involvement and
poor survival and was, furthermore, an independent predictor for disease-free
survival (Itoh et al., 2003).
COX-2 and breast cancer
In the Western world, breast cancer is the most common cancer in women,
although in recent years lung cancer has surpassed breast cancer as their leading
cause of cancer death (Jemal et al., 2002). Although epidemiological studies
indicate that use of NSAIDs is associated with reduced risk for cancers of the
digestive tract (Thun, 1994), association of NSAIDs with breast cancer incidence
is less clear. Early studies found a lower incidence of breast cancer in patients
with rheumatoid arthritis taking NSAIDs for pain relief (Baron, 1995). Most
epidemiological studies have reported an at least 20% to 40% reduction in breast
cancer risk with regular use of aspirin or other NSAIDs (Schreinemachers and
Everson, 1994; Harris et al., 1995; Harris et al., 1996; Harris et al., 1999; Neugut
et al., 1998; Sharpe et al., 2000; Johnson et al., 2002; Harris et al., 2003; Kim et
al., 2003; Garcia Rodriguez and Gonzalez-Perez, 2004;), while other studies have
found no association (Egan et al., 1996; Coogan et al., 1999; Langman et al.,
2000). The data collected and questions asked varied between the studies, and
other NSAID use besides aspirin was not completely reported or not separated
from aspirin use. A recent meta-analysis suggests, however, that NSAIDs may
reduce risk for breast cancer (Khuder and Mutgi, 2001). Its combined results from
six cohort studies and eight case-control studies gave a combined estimate of a
20
reduced relative risk of 0.82 (95% confidence interval 0.75-0.89). Interestingly,
one of these reports showed that regular aspirin use reduced risk for breast cancer
especially in hormone-receptor-positive patients (Terry et al., 2004).
COX-2 expression in breast cancer
The role of the PG pathway in breast cancer was first indicated by reports of
elevated PG levels in breast carcinomas (Bennett et al., 1977). A high
concentration of PGE2 was associated with development of metastasis, lack of
hormone receptors, and poor survival (Rolland et al., 1980). Early studies of COX-
2 mRNA and protein expression in invasive breast cancer yielded inconsistent
findings, with expression reported in between 0% and 100% of samples. COX-2
expression was detected by RT-PCR in all 13 breast cancers studied, but was not
detected in normal tissue specimens, and immunohistochemistry revealed COX-2
protein in tumor cells but not in stromal cells (Parrett et al., 1997). No COX-2
expression was found in normal breast tissue specimens, but COX-2 mRNA
expression was detected in all 21 cancer samples (Brueggemeier et al., 1999). In
contrast, COX-1 was elevated in the stroma in 30 of 44 samples studied by
Western blotting, but COX-2 was elevated in only 2 of 44 of these tumors (Hwang
et al., 1998). Immunohistochemical studies of COX-2 expression have produced
more consistent findings, with high COX-2 expression in 17 to 56% of invasive
breast cancers (Ratnasinghe et al., 2001). Soslow et al. (2000) found
immunohistochemical evidence of moderate to strong levels of COX-2 expression
in 41% of invasive breast cancer and in 80% of ductal carcinoma in situ (DCIS)
surrounding the invasive cancer. Consistent with this, several other studies have
reported higher COX-2 expression in DCIS than in invasive breast carcinomas
(Half et al., 2002; Watanabe et al., 2003; Boland et al., 2004b). Furthermore, a
recent report suggested that COX-2 is upregulated in the DCIS but is even more
upregulated in normal adjacent epithelium (Shim et al., 2003), which suggests the
hypothesis that in DCIS the surrounding epithelial tissue is part of the disease
process. The same group later reported that in normal human breast epithelium,
overexpression of COX-2 coincides with focal areas of INK4a hypermethylation
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(Crawford et al., 2004). They argued further that these focal areas might represent
early neoplastic changes later leading to breast cancer.
Animal studies
COX-2 protein has been detected in carcinogen-induced rat models of mammary
tumorigenesis (Nakatsugi et al., 2000). Levels of COX-2 protein are elevated in
mammary tumors of MMTV/neu transgenic mice (Howe et al., 2002), and COX-2
is transcriptionally upregulated in Wnt-1 expressing mouse mammary epithelial
cell lines (Howe et al., 1999). In addition, mammary epithelial cells transformed
by src or ras oncogenes produce increased amounts of COX-2 mRNA and PGE2
(Subbaramaiah et al., 1996).
Carcinogen-induced rat mammary tumors have served as a model system to test
various NSAIDs and selective COX-2 inhibitors as chemopreventive agents.
Ibuprofein reduces tumor volume in 7,12-dimethylbenz(a)anthracene (DMBA) -
induced rat mammary carcinomas (Robertson et al., 1998), with similar results in
studies using indomethasin (McCormick et al., 1985; Lala et al., 1997). Several
recent studies have evaluated the effects of selective COX-2 inhibitors on
mammary tumorigenesis in rats. Harris et al. (2000), studying the effect of
celecoxib against DMBA-induced mammary carcinogenesis, found it to reduce
incidence, multiplicity, and volume of mammary tumors. Another COX-2
selective inhibitor, nimesulide, reduced incidence, size, and multiplicity of 2-
amino-1-methyl-6-phenylimid-azo[4,5-b]pyridine (PhIP) -induced rat mammary
tumors (Nakatsugi et al., 2000). Furthermore, the chemopreventive effect of
celecoxib is dose dependent, with increasing doses of inhibitor resulting in
decreasing tumor incidence, multiplicity, and volume (Abou-Issa et al., 2001). In
addition, selective COX-2 inhibitors may play a role in the treatment of
established breast cancer, since rats treated with celecoxib after DMBA had a
diminished tumor volume and number (Alshafie et al., 2000). In addition to COX-
2, COX-1 may also play a role in mammary carcinogenesis, since Kundu and
Fulton (2002) reported that in mice COX-2 as well as COX-1 selective inhibitors
can inhibit the growth and metastatic capacity of mammary tumors.
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Inhibition of COX-2 has reduced growth of the primary tumor and number and
incidence of spontaneous metastases in an orthotopic model of breast cancer
(Connolly et al., 2002), accompanied by increased apoptosis and decreased
microvessel density in the primary tumor. Similarly, after excision of the primary
tumor, COX-2 inhibitor treatment has significantly reduced burden, number, and
size of spontaneous lung metastases (Roche-Nagle et al., 2004), with these
reductions accompanied by increased apoptosis and decreased microvessel
density in the pulmonary metastases. Apparently, COX-2 inhibition therefore not
only reduces metastasis by reducing the growth of the primary tumor but also
inhibits metastasis. Most strikingly, a recent study demonstrated that expression of
COX-2 under an MMTV promoter in the mammary glands is sufficient to induce
mammary tumors in transgenic mice (Liu et al., 2001). Virgin females did not
develop tumors, but more than 85% of the multiparous mice did, and MMTV-
driven COX-2 expression increased during pregnancy, suggesting a basis for the
failure of the virgin animals to develop tumors. The same group reported that
PGE2 induces tumor-associated angiogenesis, and this is required for the initiation
or progression of mammary cancers or both in MMTV-COX-2 mice. Furthermore,
this induction was already evident at the earliest stage of tumor development,
even prior to mammary gland hyperplasia (Chang et al., 2004).
COX-2 related factors in breast cancer
HER-2
HER-2 (also known as ErbB2) is overexpressed or amplified or both in a number of
human cancers, including breast cancer (Hynes and Stern, 1994). It is
overexpressed in approximately a third of the primary breast carcinomas, and this
overexpression is associated with decreased survival (Slamon et al., 1987). No
ligand has been shown to bind directly to HER-2, but it is activated upon ligand
binding to other HER receptors. HER-2 then is thought to function as a coreceptor
for other members of the HER family.
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Several studies have shown a connection between COX-2 and HER-2 genes. In
colorectal cancer cells, activation of HER-2/HER-3 heterodimers by heregulin
induces COX-2 promoter activity, mRNA and protein expression, and production
of PGE2 (Vadlamudi et al., 1999). HER-2 expression can, when transfected to
breast carcinoma cell lines, induce expression of COX-2 through ras/raf/MAPK
signaling and enhanced AP-1 binding (Subbaramaiah et al., 2002). Transfection of
HER-2 to breast cancer cells enhances COX-2 gene transcription (Kiguchi et al.,
2001) through the Ras/MAPK/AP-1 pathway (Subbaramaiah et al., 2002) or
through the Akt pathway (Simeone et al., 2004). COX-2 is overexpressed in the
tumors of MMTV/neu transgenic mice, and celecoxib reduces the incidence of
mammary tumors in this model (Howe et al., 2002).
In clinical breast cancer samples, Subbaramaiah et al. (2002) found high levels of
COX-2 protein in 14 of 15 microdissected HER-2-positive breast cancer samples.
This was in contrast to the 14 HER-2-negative tumors, with COX-2 expressed in
only 4 of the cases. In addition, nuclear HER-2 can associate with a specific
sequence in the COX-2 promoter and upregulate expression of the COX-2 gene
(Wang et al., 2004). Finally, recent data suggest a regulatory loop between these
two genes, since COX-2-derived PGE2 can regulate HER-2 gene expression in
breast cancer cells (Benoit et al., 2004).
Aromatase
Aromatase (estrogen synthetase) is a cytochrome P450 enzyme complex that
converts androgens to estrogens. Approximately two-thirds of breast cancers show
aromatase activity (Silva et al., 1989), which results in locally high levels of
estrogen production that can lead to stimulation of tumor proliferation. PGE2 can
stimulate aromatase expression both in the tumor itself and in the surrounding
adipose tissue (Figure 2). In adipose tissue, aromatase is normally expressed from
promoter I.4, whereas in adipose tissue adjacent to breast tumors, the aromatase
gene CYP19 is expressed from promoter II. PGE2 elevates intracellular cAMP
levels and stimulates aromatase expression by activating the promoter II region of
the CYP19 gene in breast adipose stromal cells (Zhao et al., 1996). In human
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breast cancer samples, expression of aromatase and COX-2 correlates in mRNA
and protein levels (Brodie et al., 2001; Brueggemeier et al., 1999).
Estrogen-mediated growth
E2
Increased aromatase
gene expression
PGE2
Breast cancer cell
Breast stromal cell
Increased COX-2 
gene expression
cAMP
Figure 2: Prostaglandin produced by breast cancer cells induces expression of
aromatase in breast stromal cells.
Aromatase inhibitors are currently under evaluation for their utility in cancer
chemoprevention. These drugs, however, suppress estrogen formation throughout
the body and may therefore lead to unwanted side-effects, particularly in bone
resorption. COX-2 inhibitors could provide a mechanism for selective suppression
of estrogen in the breast. Clinical studies of the chemopreventive use of COX-2
inhibitors are underway to test their effect in breast cancer.
Hormone receptors
Approximately one-third of all breast cancer patients and two-thirds of the
postmenopausal ones have hormone-dependent breast cancer, which contains
estrogen receptors and requires estrogen for tumor growth. Because estrogens
bind to specific nuclear receptor proteins where they induce growth and
proliferation of breast epithelial cells and estrogen-dependent breast cancer cells,
deprivation of estrogen signaling is an important form of therapy for patients with
estrogen receptor positive or progesterone receptor positive disease. Thus far,
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tamoxifen, an antagonist that blocks the binding of estrogen to its receptor, has
been the most widely used. That mortality rate from breast cancer has declined
during the last decade is thought to be chiefly due to the use of tamoxifen (Ali and
Coombes, 2002). Because tamoxifen can, however, especially during late disease,
begin to act as an agonist, aromatase inhibitors have gained attention as inhibitors
of estrogen synthesis. Clinical data have shown that aromatase inhibitors are so
efficient that they may in the future replace tamoxifen therapy (Johnston and
Dowsett, 2003).
Taking into account the fact that PGs, by stimulating aromatase gene expression,
stimulate estrogen biosynthesis, the ability of NSAIDs to protect against breast
cancer can vary depending on a patient's hormone-receptor status. This
hypothesis was tested in a recent study in which regular use of aspirin reduced
risk for invasive or in situ breast cancer by 20%, and this reduction was more
pronounced for women with hormone (estrogen and/or progesterone) receptor-
positive tumors (Terry et al., 2004). This result is consistent with preclinical and
clinical observations that COX-2 can induce aromatase expression and estrogen
biosynthesis (Zhao et al., 1996; Brueggemeier et al., 1999; Brodie et al., 2001).
Clinical trials are underway on the efficacy of COX-2 inhibitors and aromatase
inhibitors in treatment of breast cancer (Chow et al., 2003).
p53
p53 is a tumor-suppressor gene involved in the control of cell cycle progression,
DNA integrity, and cell survival. Wild-type p53 inhibits COX-2 expression in cell
culture (Subbaramaiah et al., 1999), so the loss-of-function p53 mutation is able
to contribute to COX-2 upregulation. In contrast, COX-2 expression is induced by
p53-mediated activation of the Ras/Raf/ERK cascade (Han et al., 2002). In clinical
studies, higher amounts of COX-2 appeared in gastric cancers containing mutant
p53 than in those containing wild-type p53 (Leung et al., 2001). Furthermore, in
colorectal cancer cells, celecoxib can inhibit wild-type p53 accumulation in the
cytosol (Swamy et al., 2003). All this raises the possibility that p53 status is one of
the determinants of COX-2 expression.
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MMP-2
MMP-2 is an extracellular matrix-degrading proteolytic enzyme linked to invasion
and metastasis (Liotta et al., 1980; Egeblad and Werb, 2002). Expression and
activity of MMP-2 in human breast cancer is elevated, and correlates with lymph-
node and distant metastasis, and with shortened survival (Talvensaari-Mattila et
al., 2003). A direct link between COX-2 and MMP-2 has been shown in several
experimental models. A COX-2 selective inhibitor suppressed the invasiveness
and proMMP-2 release of prostate cancer cells (Attiga et al., 2000), and in non-
small cell lung carcinoma cells, PGE2 induced invasion and expression of MMP-2
(Dohadwala et al., 2002).  In line with these data, a selective COX-2 inhibitor has
been shown to reduce MMP-2 promoter activity, which was partially reversed by
administration of PGE2 (Pan et al., 2001). In addition, transfection of COX-2
elevated the activation of MMP-2 in human breast and colon cancer cells (Tsujii
et al., 1997), and a recent study showed in a mouse model of colorectal cancer
that the COX-2 selective inhibitor rofecoxib can reduce metastasis and reduce
expression of MMP-2 (Yao et al., 2003). In a clinical series, Miyata et al. (2003)
showed that expression of COX-2 correlates with expression of MMP-2 in renal
cell carcinoma and that both of these factors associate with reduced survival.
COX-2 in esophageal carcinoma
Esophageal carcinoma exists in two main forms, adenocarcinoma and squamous
cell carcinoma (Figure 3). More than 90% of esophageal cancers worldwide are
squamous cell carcinomas, but adenocarcinomas are more prevalent in Western
countries, in which incidence of esophageal adenocarcinoma has increased
dramatically over the last decades, a rise being faster than for any other solid
tumor (Chow et al., 1995; Devesa et al., 1998). The cause for this epidemiological
change remains in part unclear. Several risk factors have been proposed; reflux
disease (Chow et al., 1995; Cameron and Romero, 2000), smoking (Castellsague
et al., 1999), dietary factors (Ribeiro et al., 1996), obesity (Chow et al., 1998b),
and changes in Helicobacter pylori infection frequencies (Chow et al., 1998a).
Reflux disease is clearly a risk factor for adenocarcinoma of the esophagus. A
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recent population-based, case-control study found a strong association between
symptomatic gastroesophageal reflux disease and risk for esophageal
adenocarcinoma (Lagergren et al., 1999). Smoking habits have not changed
sufficiently to explain changes in incidence, but obesity has increased during the
last decades in the USA and Europe. Indeed, a multicenter population-based case-
control study showed that obesity is a strong risk factor for adenocarcinoma of the
esophagus (Chow et al., 1998b). Because Helicobacter pylori infection apparently
protects against Barrett’s esophagus and adenocarcinoma (Chow et al., 1998a),
the decrease in Helicobacter pylori infections may thus explain some of the
increase in incidence of esophageal adenocarcinoma. It is now generally
accepted that most, if not all, adenocarcinomas of the esophagus develop from a
premalignant lesion of the esophagus called Barrett’s esophagus (Cameron et al.,
1995). In Barrett’s esophagus, normal esophageal squamous epithelium in the
lower esophagus is replaced by metaplastic columnar intestinal-type epithelium
(Spechler and Goyal, 1996) (Figure 3). Patients with Barrett’s esophagus are at risk
for developing dysplasia leading to adenocarcinoma.
In contrast to esophageal adenocarcinoma, in Western countries the incidence of
esophageal squamous cell carcinoma has remained the same or decreased over
recent decades (Devesa et al., 1998). Its incidence shows great geographical
variation in incidence and mortality. That it occurs at high frequencies in certain
parts of the world points to specific environmental factors playing a role in its
etiology. In developed countries, its etiology has been mainly attributed to
tobacco smoking and heavy alcohol drinking (Castellsague et al., 1999).
Consumption of certain foods or hot beverages and microbial toxins has also been
connected to its pathogenesis especially in high-incidence areas (Ribeiro et al.,
1996). The principal precursor lesion of esophageal squamous cell carcinoma is
dysplasia (Figure 3).
Esophageal carcinomas are highly lethal diseases, the overall 5-year survival for
patients with advanced disease being less than 20%. Existing treatment modalities
are therefore insufficient, and new preventive and treatment strategies are needed.
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Among epidemiological studies of esophageal cancer, most have indicated that
reduced risk is associated with use of NSAIDs (Funkhouser and Sharp, 1995;
Farrow et al., 1998; Langman et al., 2000; Kim et al., 2003). Consistent with this,
a recent meta-analysis suggests that NSAIDs are protective against both
esophageal adenocarcinoma and squamous cell carcinoma; combining results
from two cohort studies and six case-control studies gives a combined estimate of
reduced relative risk of 0.67 (95% CI 0.51-0.87) for adenocarcinoma and 0.58
(95% CI 0.43-0.78) for squamous cell carcinoma (Corley et al., 2003).
Figure 3: Two types of esophageal carcinoma.
COX-2 expression in esophageal carcinoma
Several studies have reported an elevated COX-2 mRNA expression in Barrett’s
metaplasias and in associated esophageal adenocarcinoma (Wilson et al., 1998;
Shirvani et al., 2000; Lagorce et al., 2003). Moreover, progression from Barrett’s
esophagus to dysplasia and invasive carcinoma is associated with an increase in
COX-2 expression (Wilson et al., 1998; Shirvani et al., 2000). Expression of COX-
2 mRNA and protein have also been reported in squamous cell carcinoma of the
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esophagus. (Ratnasinghe et al., 1999; Shamma et al., 2000; Kawabe et al., 2002;
Kuo et al., 2003; Maaser et al., 2003). Again, expression of COX-2 increases
progressively when nonneoplastic esophageal tissues are compared to dysplastic
or to invasive lesions (Shamma et al., 2000).
Experimental studies
In vivo and in vitro studies both support a possible role for COX-2 in esophageal
cancer. Buttar et al. (2002a) demonstrated in primary cultured endoscopic biopsy
specimens from patients with Barrett’s esophagus that the selective COX-2
inhibitor NS-398 reduces COX-2 activity and proliferation of epithelial cells.
These same investigators found that in a surgically induced rat reflux model, both
the non-selective COX-2 inhibitor sulindac and selective COX-2 inhibitor MF-
Tricyclic prevent development of Barrett’s esophagus and esophageal
adenocarcinoma (Buttar et al., 2002b). In a rat model of bile-induced esophageal
carcinogenesis, COX-2 expression is induced, and the selective COX-2 inhibitor
NS-398 suppresses this expression (Kaur et al., 2000). In cell culture, the selective
COX-2 inhibitors NS-398 and rofecoxib suppress cellular growth and induce
apoptosis in human esophageal adenocarcinoma and squamous cell carcinoma
cells (Souza et al., 2000; Vona-Davis et al., 2004). It is unknown how COX-2 is
upregulated in adenocarcinomas of the esophagus, but since bile acids induce
COX-2 expression in a rat model (Zhang et al., 2001) and in Barrett’s explants
(Shirvani et al., 2000), it is possible that reflux disease may induce the early
expression of COX-2 during the development of the Barrett’s metaplasia. Finally,
Kaur et al. (2002) indirectly demonstrated the possible chemopreventive effect of
selective COX-2 inhibitors. When biopsy specimens of human Barrett’s
epithelium were compared with biopsy specimens obtained after 10 days of
rofecoxib therapy, a decrease had occurred in COX-2 expression and in PGE2
content.
In esophageal squamous cell carcinoma cells, both aspirin and NS-398 can
induce apoptosis (Li et al., 2000; Li et al., 2001a). In respect to chemically
induced squamous cell tumors in the rat, the data are conflicting, since a COX-2
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selective inhibitor has been found to reduce incidence of both noninvasive and
invasive lesions (Li et al., 2001b), whereas the NSAID piroxicam failed to reduce
tumorigenesis (Carlton et al., 2002). In a diethylnitrosamine-induced mouse
model of esophageal squamous cell carcinoma, NSAID indomethasin is able to
reduce tumor incidence (Rubio, 1986). Finally, in a mouse model created for
human oral-esophageal cancer, sulindace reduced development of severe
dysplasia in the esophagus (Opitz et al., 2002).
COX-2 and chemo- and radiotherapy
Results from preclinical and clinical studies suggest a link between COX-2
expression and response to chemo- and radiotherapy treatment. In animal models,
the selective COX-2 inhibitors SC-236 and JTE-522 can enhance the efficacy of
chemotherapy or radiation treatment (Milas et al., 1999; Hida et al., 2002). The
selective COX-2 inhibitor NS-398 has enhanced the effect of radiotherapy in vivo
on lung cancer xenocrafts and in vitro on human COX-2-overexpressing cells (Pyo
et al., 2001), and no radiation-enhancing effect occurred in the cells deficient in
COX-2 expression. In a rat model of colorectal cancer, celecoxib enhanced the
antitumor effect of a chemotherapeutic agent and reduced the side-effect of
diarrhea (Trifan et al., 2002). Furthermore, the selective COX-2 inhibitor SC-236
does not affect the radiotherapy response of normal tissue (Kishi et al., 2000),
probably due to the lack of COX-2 expression in normal mouse tissue. Moreover,
celecoxib enhances the effects of the chemotherapeutic agent docetaxel and of
radiation or of both in nude mice (Nakata et al., 2004). In carcinoma cell lines,
the selective COX-2 inhibitors nimesulide, SC-236, and NS-398 enhance the
radioresponsiveness and cytotoxicity of several chemotherapeutic agents (Hida et
al., 2000; Petersen et al., 2000; Amirghahari et al., 2003). Finally, in vitro studies
and one in vivo study show that radiation or chemotherapeutic agents can
enhance expression of COX-2 (Steinauer et al., 2000; Subbaramaiah et al., 2000;
Subbaramaiah et al., 2003; Davis et al., 2004;).
In respect to clinical evidence, Ferrandina et al. (2002) demonstrated that in
locally advanced cervical cancer patients, receiving neoadjuvant chemotherapy,
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COX-2 expression increased progressively from responders to partial responders
to non-responders. Furthermore, COX-2-positive patients had a shorter overall
survival than did COX-2-negative patients. In oral squamous cell carcinoma
patients, low expression of COX-2 is associated with a patient's radiation
sensitivity (Terakado et al., 2004). In a very recent study, for esophageal
squamous cell carcinoma patients but not for esophageal adenocarcinoma
patients, low COX-2 expression, when detected immunohistochemically in
pretreatment biopsy specimens, predicted treatment response. Pretreatment COX-
2 expression was not, however, associated with their survival (Kulke et al.,
2004b). In laryngeal cancer, COX-2 may have prognostic value in predicting
response to radiotherapy failure (Nix et al., 2004). Furthermore, in clinical studies
of patients with cervical or ovarian cancer receiving adjuvant chemotherapy or
radiotherapy, high COX-2 expression associates with resistance to treatment and
to reduced overall survival (Gaffney et al., 2001; Kim et al., 2002; Wulfing et al.,
2004). Finally, a phase-II trial recently demonstrated that in non-small-cell lung
cancer, celecoxib enhances the response to neoadjuvant paclitaxel and
carboplatin treatment (Altorki et al., 2003).
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AIMS OF THE STUDY
The purpose of this study was to investigate whether expression of COX-2 protein,
as detected by immunohistochemistry, is associated with clinicopathological
parameters and clinical outcome in human breast and esophageal cancer patients.
The specific aims of the present study were:
- To investigate the prognostic significance of COX-2 in breast carcinoma.
- To correlate COX-2 expression with expression of MMP-2 and with other
gene products relevant in breast cancer (HER-2, ER, PR, p53).
- To study the prognostic significance of COX-2 in adenocarcinoma and
squamous cell carcinoma of the esophagus.
- To study the prognostic significance of COX-2 in neoadjuvant-treated
patients with esophageal squamous cell carcinoma.
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MATERIALS AND METHODS
Patients
Breast cancer and esophageal cancer specimens were obtained from several
hospitals in Finland and the Netherlands. Information about the patients is in
Table 4. All studies were done in accordance with the guidelines of the local
ethics committees.
Table 4: Summary of patient samples for this work.
Study Tumor type Number of
samples
Sample type Origin
I Invasive breast
cancer
1576 Tissue array FinProg, Finland
II Invasive breast
cancer
278 Tissue array Helsinki University
Central Hospital,
Finland
III Esophageal
adenocarcinoma
145 Histologic Academic Medical
Center, Amsterdam,
the Netherlands
IV Esophageal
squamous cell
carcinoma
117 Histologic Academic Medical
Center, Amsterdam,
the Netherlands
Study I: Five well-defined geographical regions, comprising approximately half
the Finnish population, were selected for the study. Using the files of the nation-
wide Finnish Cancer Registry, all women diagnosed from 1991 to 1992 with
breast cancer were identified. With structured data collection forms, clinical data
of 50 characteristics were extracted from hospital records. A total of 2842 patients
(93% of all breast cancer patients) with sufficient clinical data available were
entered into the database (= the FinProg Breast Cancer Database), of whom 1984
were included the study. Patients with in situ carcinomas (n = 201), those with
distant metastasis at the time of diagnosis (n = 133), those with synchronous or
metachronous bilateral breast cancer (n = 281), those with malignancy other than
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breast cancer in their history except for basal cell carcinoma or cervical in situ
carcinoma (n = 201), and those who underwent no breast surgery (n = 42) were
excluded. The median follow-up for patients alive at the end of follow-up was 6.8
years (range 5.1-7.8).
Study II: The patient series comprised 278 other breast cancer cases treated at the
Fourth Department of Surgery of the Helsinki University Central Hospital from
1987 to 1990, whenever a histological specimen was available in the pathology
files. Onto structured data collection forms, the clinical data of the patients were
extracted from the hospital records, which were reviewed. The median follow-up
time for patients alive at the end of the study period was 10.1 years (range from
0.3 to 12.6 years).
Studies III and IV: Between 1 January 1993 and 31 December 2000, 306 patients
underwent esophageal resection for adenocarcinoma of the esophagus or gastro-
esophageal junction, and 504 underwent esophageal resection with proximal
gastrectomy for an esophageal malignancy with curative intent (had locally
resectable disease without distant metastases) at the Department of Surgery of the
Academic Medical Center, Amsterdam, the Netherlands.
For Study III, the data from original 306 patients were prospectively collected in a
database. All pathology reports were reviewed to identify those who had
undergone surgery for adenocarcinoma developed in a histologically proven
Barrett’s esophagus, defined by the presence of goblet cells. Patients with an
adenocarcinoma of the cardia or gastro-esophageal junction with no Barrett’s
segment were excluded (n = 155). Archival material from the remaining 151
patients was re-evaluated by two of the investigators to obtain the sample with the
deepest invasion of each tumor. Another six specimens were excluded during the
immunohistochemical analyses (three samples with no definitive invasive cancer,
two with adenosquamous carcinoma, and one that repeatedly detached from the
slide), so that only the 145 patients remaining were included. Patients were
followed until 30 June 2001 or until death, ensuring a minimal follow-up of 6
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months (median 38.2 months; range 8 days to 7.3 years). We included all deaths
following surgery, including two perioperative deaths.
For Study IV, the pathology reports of all 504 patients were reviewed to identify
138 patients diagnosed with a squamous cell carcinoma of the esophagus. During
review of the slides, 13 tumors with adenosquamous characteristics were
excluded, and another 8 patients were excluded during immunohistochemical
analyses for having non-representative archival slides compared to the original
tumor. Thus, 117 patients were included in the study. Patients were followed until
death or December 2003, ensuring a minimal potential follow-up of 3 years. The
median actual follow-up was 33.0 months (range 7 days to 8.5 years). No patient
was lost to follow-up. Four (3.4%) who died in the hospital within 30 days were
included in the analyses.
Neoadjuvant treatment
In Study IV, 36 esophageal squamous cell carcinoma patients received
chemotherapy preoperatively as part of a randomized controlled trial: cisplatin
(CddP; 80 mg/m2 iv day 1) and etoposide (E; 100 mg iv day 1+2; 200 mg/m2 orally
days 3+5). After two cycles of chemotherapy, clinical response was evaluated
based on clinical findings such as decrease in dysphagia and on repeated
endoscopy and in CT scanning. Patients with a tumor response received another
two cycles followed by surgery, whereas non-responding patients underwent
surgery after the second cycle. No adjuvant treatment was administered
postoperatively.
Preparation of breast tumor tissue arrays
Studies I and II incorporated routinely fixed (overnight in 10% buffered formalin)
paraffin-embedded tumor samples stored in the files of pathology laboratories.
Histopathologically representative tumor regions were defined from hematoxylin-
and eosin-stained sections and marked on each slide. Tumor tissue array blocks
were made by punching a tissue cylinder (core), diameter 0.6 mm, through a
histologically representative area of each ”donor” tumor block, which was then
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inserted into an empty ”recipient” tissue array paraffin block with a specialized
instrument (Kononen et al., 1998). In Study I, from the 1728 tumor samples
available, 19 tissue array blocks were prepared, each containing 50 to 144 tumor
samples. For Study II, from the 278 tumor samples available, 4 tissue array blocks
were prepared, each containing 36 to 144 tumor samples. Sections of 5 µm were
cut and processed for immunohistochemistry. Consecutive sections of each
sample were used for COX-2 and MMP-2 immunostaining (II).
Immunohistochemistry
For COX-2 immunostaining (I-IV), formalin-fixed and paraffin-embedded
specimens representing the deepest tumor infiltration were sectioned (5 µm),
deparaffinized, and microwaved for 4 x 5 min in 700 W in 0.01 M Na-citrate
buffer (pH 6.0) for antigen retrieval. The slides were then immersed in 0.6%
hydrogen peroxide in methanol for 30 min to block endogenous peroxidase
activity and in blocking solution (1.5:100 normal horse serum in PBS) for 15 min
to block unspecific binding sites. Immunostaining was performed with a COX-2-
specific mouse anti-human monoclonal antibody (160112, Cayman Chemical
Co., Ann Arbor, MI, USA) in a dilution of 1:200 (2.5 µg/ml) in PBS containing
0.1% sodium azide and 0.5% bovine serum albumin at room temperature
overnight. Then the sections were treated with biotinylated horse anti-mouse
immunoglobulin (1:200; Vector Laboratories Inc., Burlingame, CA, USA) and
avidin-biotin peroxidase complex (Vectastain ABComplex, Vector Laboratories).
The peroxidase staining was visualized with 3-amino-9-ethylcarbazole (Sigma
Chemical Co., St. Louis, MO, USA), and the sections were counterstained with
Mayer's hematoxylin. Every 20th sample of the trial series was a known colon
adenocarcinoma specimen, in which stromal cells in an area of ulceration were
scored 3, cancer cells from 2 to 3, and adjacent nonneoplastic epithelium 1 (for
scoring criteria see below). This procedure confirmed that there was no significant
intra- and interassay variability in staining intensity, and helped us to score the
trial specimens. Recently, we evaluated several COX-2 antibody preparations, and
concluded that the monoclonal antibody used in this study provided us with the
most specific and reproducible immunoreactivity (Saukkonen et al., 2001).
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Antibody specificity was confirmed by staining one breast tumor tissue array slide
(I) or a randomly selected subset of esophageal adenocarcinoma specimens (every
10th sample, n = 15) (III) with and without preadsorption of the primary antibody
with human COX-2 control peptide (10 µg/ml, Cayman); all cancer cell positivity
was blocked by this control procedure.
For MMP-2 immunostaining (II), the breast tissue array specimens were treated
with 0.4% pepsin (Sigma) for 20 min at 37°C. Endogenous peroxidase activity was
blocked by incubating the slides in 3% hydrogen peroxide in absolute methanol
for 15 min, and nonspecific binding was blocked with 10% goat serum for 15
min. A mouse monoclonal antibody (CA-4001, Diabor Ltd., Oulu, Finland) to
MMP-2 served as the primary antibody (6 µg/ml in 0.01 M phosphate buffer, 0.9%
NaCl, pH 7.5), with 1% bovine serum albumin. This antibody recognizes the
amino terminal end of the latent MMP-2 both as a free enzyme and when it is in
complex with a tissue inhibitor of metalloproteinase-2. Its specificity has been
confirmed by a Western blot analysis (Höyhtyä et al., 1994). The specimens were
incubated for 60 min at room temperature. The sections were then treated with
biotinylated anti-mouse IgG (for COX-2; 1:200, Vector Laboratories, and for
MMP-2; Zymed, San Francisco, CA, USA) and the avidin-biotin peroxidase
complex was introduced. The peroxidase staining was visualized with 3-amino-9-
ethylcarbazole (Sigma), and the sections were counterstained with Mayer’s
hematoxylin.
For p53 immunostaining (IV), the esophageal squamous cell carcinoma specimens
were stained by established procedures (Lundin et al., 1996). Expression of p53,
HER-2, ER, and PR (I, II) had previously been determined for breast cancer tissue
array datasets. Immunostaining of ER, PR, Ki-67, and p53 was done by established
procedures (Järvinen et al., 1998). HER-2 gene amplification had been assessed by
chromogenic in situ hybridization (Tanner et al., 2001).
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Scoring of immunostaining
For evaluating COX-2 immunohistochemical staining, the following scoring
criteria for the tumor cells were agreed upon before analysis: 0, no staining; 1+,
weak diffuse cytoplasmic staining (may contain stronger intensity in less than 10%
of cancer cells); 2+, moderate to strong granular cytoplasmic staining in 10 to
90% of cells; 3+, over 90% stained with strong intensity. Scores 0 and 1 were
categorized as "COX-2 low" and scores 2 and 3 as "COX-2 high" for the statistical
analyses.
In Study I, COX-2 immunohistochemical staining was scored in breast tissue array
samples independently and in a blinded manner by two investigators from 1728
tissue array cores, of which 152 (8.8%) either became detached or contained no
tumor cells. The percent agreement between the two independent and blinded
investigators in allocation of the tumors into these two categories was 85%. The
corresponding kappa value was 0.69, which can be interpreted as a good level of
agreement. All specimens with discordant scores were re-evaluated by the two
investigators with a multiheaded microscope, and the consensus score was used
for further analyses. In Study II, COX-2 immunohistochemical staining was scored
for 231 breast tissue array cores (of 278 samples, 20 were detached, and 27
contained no tumor cells). Discordant scores (92% of the specimens were
categorized identically) were re-evaluated by the investigators, and this consensus
score served for further analysis. COX-2 immunohistochemical staining was
evaluated in all esophageal adenocarcinoma and squamous cell carcinoma
specimens (III, IV) independently and in a blinded manner by two investigators.
Allocation of tumors to the "COX-2 low" versus "COX-2 high" category by the two
investigators was similar (> 95% (III), and 93% (IV) of the specimens categorized
identically). In cases of disagreement (n = 6 (III) and n = 9 (IV)) the slides were re-
evaluated by a group of investigators with a multiheaded microscope.
MMP-2 immunohistochemical staining (II) was scored from 194 tissue array cores
(of 278 samples, 26 were detached, and 58 contained no tumor cells). A section
was considered negative or positive based on the absence or presence of
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cytoplasmic staining; staining was scored as follows: 0, no positive cells; 1, <
20% of the tumor cells staining positive; 2, 20 to 50% staining positive; 3, > 50%
positive. Three independent observers scored immunostaining; discordant scores
(2%) were re-evaluated by the investigators, with the consensus score used for
further analysis.
Immunoreactivity of p53 (IV) was considered weakly positive if 0 to 50% of the
tumor cells were immunopositive, and strongly positive if 50 to 100% of the
tumor cells was immunopositive. The presence of any necrosis was evaluated
from HE-stained samples.
Statistical analysis
The associations between factors were assessed by Chi-square test (categorical
data) (I-IV) and Student's t-test (continuous data) (III, IV). The odds ratio served to
examine the strength of the relationships (I). Life-tables were calculated according
to the Kaplan-Meier method and compared by the log-rank test. Distant disease-
free survival (DDFS) was calculated from date of diagnosis to occurrence of
metastases outside the locoregional area or death from breast cancer, whichever
came first. Disease-specific survival was calculated from date of diagnosis to
death from breast cancer, censoring deaths from intercurrent causes. Overall
survival was calculated from date of diagnosis to death from any cause.
Multivariate survival analyses (I, III, IV) were performed with the Cox proportional
hazards model. The following covariates were entered: Study I: COX-2 expression
(score 0-1 vs. 2-3), age of patient (< 50 vs. ≥ 50 years), number of metastatic
lymph nodes (continuous), tumor size in centimeters (continuous), histologic
grade (well-differentiated vs. moderately to poorly differentiated), histologic type
(nonductal vs. ductal), ER (positive vs. negative), PR status (positive vs. negative),
HER-2 amplification (negative vs. positive), Ki-67 expression (< 20% vs. ≥ 20%
positive tumor cells) and p53 expression (< 20% vs. ≥ 20% positive tumor cells).
Studies II and IV: Age, gender, operation type, and variables related to tumor
characteristics such as differentiation grade, tumor stage, and radicality of the
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resection were included in this model. Variables with multiple categories were
recoded into dichotomous variables by combining categories with comparable
prognosis (differentiation grade: well versus moderate to poor; radicality of
resection: microscopically radical (R0) versus microscopically nonradical (R1) and
macroscopically nonradical (R2); tumor stage: stage I and IIa versus IIb, III, and
IV). A P value of 0.05 was adopted as the limit for inclusion of a covariate.
All of the statistical tests were two-sided, and P values of 0.05 or below were
considered statistically significant. Statistical analyses were performed with the
Statistical Software Package version 9.0 (I, III) or 11.0 (II, IV) (SPSS Inc., Chicago,
IL, USA).
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RESULTS
COX-2 in breast cancer
Prognostic significance of COX-2 in breast cancer
In Study I, immunoreactivity of COX-2 was evaluated in 1576 invasive breast
carcinomas, of which 37.4% stained with high intensity. In Study II, expression of
COX-2 protein was analyzed in 231 invasive breast carcinoma specimens, of
which 30% stained with high intensity. In both studies, high COX-2
immunoreactivity was localized exclusively to the cytoplasm and sometimes to
the perinuclear region of the cancer cells, whereas the stroma was either negative
or only weakly positive.
In Study I, elevated expression of COX-2 was significantly more frequent in ductal
carcinomas (39.9%) as compared to lobular (29.5%) or special (30.8%; tubular,
medullary, mucinous, and papillary) histologic types (P = 0.0017). In the group of
ductal tumors, COX-2 was associated with high histologic grade (P < 0.0001).
Elevated COX-2 expression was more common in tumors with large size, negative
hormone receptor status, high Ki-67 expression, high p53 expression, or HER-2
amplification (P < 0.0001 for each comparison). A significant association also
appeared with the presence of axillary lymph node metastases (P = 0.0001). No
significant association existed between COX -2 and age at diagnosis when 50
years was used as the cut-off value. In Study II, high COX-2 expression was more
common in tumors of larger size (P = 0.041), negative estrogen receptor status (P
= 0.026), and negative progesterone receptor status (P < 0.001). In the group of
ductal tumors, COX-2 expression associated with high histologic grade (P =
0.003).
In both studies, elevated COX-2 expression was associated with decreased
disease-specific survival. In Study I, among the 1576 breast cancer patients
eligible for survival analysis, this was evident when the COX-2 high category was
compared to the COX-2 low category (P < 0.0001; log-rank test). Kaplan-Meier
curves for disease-specific survival are depicted in Figure 4A. In Study II, high
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COX-2 expression associated also with decreased disease-specific survival (P =
0.026; log-rank test). Kaplan-Meier curves are depicted in Figure 4B.
Figure 4: Kaplan-Meier curves for patients with a breast cancer. A: Disease-
specific survival of 1576 patients with breast cancer according to COX-2
expression. There were 987 patients with COX-2 low expression and 589 with
COX-2 high expression. A statistically significant difference was observed
between the groups (P < 0.0001; log-rank test). B: Disease-specific survival of 231
breast cancer patients based on COX-2 expression: 161 patients with COX-2 low
expression, 70 with COX-2 high expression. Significant difference was observed
between the groups (P = 0.026; log-rank test).
Interestingly, in Study II, we observed that the prognostic impact of COX-2 among
subgroups of patients differed. Elevated COX-2 expression predicted poorer
survival for patients with ER-positive tumors (P = 0.008; log-rank test) (Figure 5),
but not significantly for the hormone receptor-negative ones. A general trend for
COX-2 to be a stronger prognostic marker in those subgroups showing features of
better prognosis was also evident in other groups (p53 negative/low, no HER-2
amplification, low proliferation rate, and small tumor size). However, dividing
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groups by axillary lymph node status made no such difference, since COX-2
expression was associated with both the node-negative and -positive carcinomas
(Table 5).
Figure 5: Distant disease-free survival of 232 patients receiving hormonal
adjuvant therapy and with estrogen-positive breast cancer, grouped according to
COX-2 expression: 137 patients with COX-2 low expression, 95 with COX-2 high
expression. Significant difference was observed between the groups (P = 0.008;
log-rank test).
Table 5: Five-year DDFS according to COX-2 expression level.
Clinicopathological parameter P-value*
Small tumor size (< 2 cm)
Large tumor size (> 2 cm)
0.013
Not significant
Node-negative
Node-positive
0.001
0.006
Grade I or 2 (ductal type only)
Grade 3  (ductal type only)
< 0.05
Not significant
Estrogen receptor positive
Estrogen receptor negative
< 0.0001
Not significant
Low rate of proliferation
High rate of proliferation
0.001
Not significant
Negative to low p53 expression
High p53 expression
< 0.0001
Not significant
No amplification of HER-2 oncogene
Amplification of HER-2 oncogene
< 0.0001
Not significant
*Log-rank test or log-rank test for a trend.
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Association of COX-2 and MMP-2 protein in breast cancer
Expression of MMP-2 protein was analyzed in 194 invasive breast carcinoma
specimens, of which 83.0% stained with high intensity. MMP-2 protein
expression localized primarily to the cytoplasm of the cancer cells. High MMP-2
expression associated with reduced disease-specific survival (P = 0.021; log-rank
test) as well as with reduced overall survival (P = 0.015; log-rank test). A
significant association existed between high COX-2 and high MMP-2 expression
(P = 0.003; Chi-square test). It was especially evident that whenever COX-2
expression was high, MMP-2 expression was almost invariably high (56 of 59).
COX-2 in esophageal cancer
Prognostic significance of COX-2 in adenocarcinoma
COX-2 immunoreactivity was detected in 79.3% of the esophageal
adenocarcinoma cases (III). COX-2 expression was mainly localized in the
neoplastic cells when squamous epithelium of the esophagus was consistently
negative or only weakly positive. A significant association appeared between
elevated COX-2 expression and development of distant metastases (P = 0.02; Chi-
square test) and locoregional recurrences (P = 0.05; Chi-square test). A significant
difference in survival was evident between patients in the “COX-2 low” when
compared to the “COX-2 high” category (P = 0.002; log-rank test) (Figure 6). As
for the role of COX-2 as an independent prognostic factor, univariate Cox
regression analysis showed a significant prognostic effect for COX-2 expression,
tumor stage, differentiation grade, and radicality of the resection, and multivariate
analysis, after adjustment for the other possibly confounding variables, showed no
change in the impact of high COX-2 expression on mortality.
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Figure 6: Kaplan-Meier curves for 145 patients with esophageal adenocarcinoma:
30 had low COX-2 expression and 115 high expression. Significant difference was
observed between groups (P = 0.002; log-rank test).
Prognostic significance of COX-2 in squamous cell carcinoma
In the 117 esophageal squamous cell carcinoma specimens, expression of COX-2
protein was evaluated by immunohistochemistry. Expression was mainly localized
in the neoplastic cells, when nonneoplastic squamous epithelium was consistently
negative or only weakly positive. Among the 81 patients receiving no neoadjuvant
chemotherapy, COX-2 immunoreactivity was high in 24.7% of the specimens.
Among the 36 receiving neoadjuvant treatment, high COX-2 immunoreactivity
occurred in 30.6%. In the patient group receiving no neoadjuvant treatment,
COX-2 expression was associated with tumor location, with a higher COX-2
expression in distal tumors (P = 0.02; Chi-square test). For the other
clinicopathological parameters, no correlation with COX-2 expression was
demonstrable, including survival (Figure 7A). In the group of 36 patients receiving
neoadjuvant chemotherapy, COX-2 expression was associated with tumor
location (P = 0.03; Chi-square test), with male gender (P = 0.02; Chi-square test),
and with response to neoadjuvant chemotherapy (P = 0.04; Chi-square test).
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Furthermore, a significant association appeared between low COX-2 expression
and development of distant metastases (P = 0.03; Chi-square test), with all of the
eight distant metastases developing in the low-COX-2 group. Although 13 of the
16 locoregional recurrences developed in that group, the difference was not
significant. COX-2 expression did not associate with overall survival in the patient
group receiving no neoadjuvant treatment. However, in those 36 patients who did
receive it, a significant association appeared between low COX-2 expression and
reduced overall survival (P = 0.02; log-rank test) (Figure 7B).
Figure 7: A: Kaplan-Meier curves for 81 patients with squamous cell carcinoma of
the esophagus not receiving chemotherapy before surgery: 61 with COX-2 low
expression and 20 with COX-2 high expression. No significant difference was
observed between groups (P = 0.4, log-rank test). B: Kaplan-Meier curves of 36
patients with squamous cell carcinoma of the esophagus receiving chemotherapy
before surgery: 25 with COX-2 low expression and 11 with COX-2 high
expression. Significant difference was observed between groups (P = 0.02, log-
rank test).
Survival in months
Survival in months
Pr
op
ab
ili
ty
 o
f o
ve
ra
ll  
su
rv
iv
al
Pr
op
ab
ili
ty
 o
f o
ve
ra
ll 
su
rv
iv
al
A
B
120100806040200
1.0
0.8
0.6
0.4
0.2
0
COX-2 High
COX-2 Low
1.0
0.8
0.6
0.4
0.2
0
120100806040200
COX-2 Low
COX-2 High
47
As for the role of COX-2 as an independent prognostic factor in the group of
neoadjuvant-treated patients, univariate Cox regression analysis showed a
significant prognostic effect for tumor stage, radicality of resection, and low COX-
2 expression. In the multivariate analysis, the impact of low COX-2 expression on
decreased overall survival persisted after adjustment for the other possibly
confounding variables. In patients receiving neoadjuvant treatment, COX-2
expression was re-analyzed and correlated with presence of necrosis and p53
immunopositivity; there appeared, however, no correlation between COX-2
expression and necrosis or p53 immunoreactivity.
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DISCUSSION
COX-2 as a prognostic factor in breast carcinoma
Our results in Study I provided the first evidence for COX-2 protein expression in
a large series of breast tumors (n = 1576). The database came from a large
population-based, multicenter study in Finland using cancer registry data. We
detected elevated levels of COX-2 protein expression in 37.4% of the tumors.
Similar results were obtained in Study II, where COX-2 protein expression was
detected in 30.3% of the samples. In our samples, strong COX-2 expression was
localized exclusively in the neoplastic cells, whereas the stroma was either
negative or only weakly positive. Consistent with our findings, others have
demonstrated immunostaining of COX-2 in epithelial cells of human breast
cancer in 17.4% to 63% of the samples (Table 7).
Table 7: COX-2 protein expression in human breast carcinoma.
Frequency of COX-2 expression
17.4% Costa et al., 2002
36% Denkert et al., 2003
40.6% Wulfing et al., 2003
41.2% Soslow et al., 2000
43% Half et al., 2002
48.6% Spizzo et al., 2003
63% Boland et al., 2004a
In Study I, COX-2 positivity correlated with many parameters characterizing the
aggressive type of breast cancers, i.e., with large tumor size, presence of axillary
lymph node metastases, high histological grade, negative hormone-receptor
status, high proliferation rate, high p53 expression, and HER-2 amplification.
Similarly in Study II, COX-2 expression was associated with tumor size over 2 cm,
high histological grade, and negative hormone-receptor status. Several other
studies confirm the association between expression of HER-2 and of COX-2 in
primary breast cancers (Subbaramaiah et al., 2002; Wulfing et al., 2003; Boland
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et al., 2004a), although some studies fail to find such association (Costa et al.,
2002; Half et al., 2002; Denkert et al., 2003).
Our main finding showed that in patients with breast cancer elevated level of
COX-2 is associated with poor survival. Data in Study II confirm results of Study I.
In both studies, COX-2 expression was associated with markers of poor prognosis,
such as tumor size over 2 cm, high histological grade, and negative hormone-
receptor status. Several recent studies using immunohistochemistry have now
confirmed our results. Denkert et al. (2003) reported in a study of 221 breast
cancer patients that high COX-2 expression is associated with poor survival.
Similar to us, they found a significant correlation between COX-2 expression and
lymph node status, tumor size, histological grade, and negative ER status, but
found no correlation with HER-2. In a study comprising 212 invasive breast
cancers, COX-2 overexpression was associated with disease-free and overall
survival (Spizzo et al., 2003); COX-2 also correlated with menopausal status and
histological tumor type but failed to correlate with any other tumor parameter. In
another study, 46 breast carcinomas showed an association of COX-2 expression
with lymph node metastasis and angiogenesis but not with any other
clinicopathological parameter including HER-2 (Costa et al., 2002), and in
addition, high COX-2 expression was associated with short disease-free survival
for the subgroup of 26 patients with survival data available. One study reported
that in 23 invasive breast cancers, elevated COX-2 expression was associated with
diminished overall and disease-free survival (O'Connor et al., 2004). A recent
study showed that in invasive breast cancers, and in DCIS, COX-2 expression is
associated with high proliferation rate, ER negativity, and with HER-2 positivity
(Boland et al., 2004a), but no survival analysis was performed. In contrast to our
results, some of the studies found no correlation between COX-2 expression and
various clinicopathological parameters including survival (Half et al., 2002; Kelly
et al., 2003). For instance, in a study involving 200 human breast carcinomas,
expression of COX-2 protein was associated, consistent with our findings, with
several markers of aggressive tumor type but not with survival (Wulfing et al.,
2003).
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Interestingly, the prognostic value of COX-2 expression tended to be significant in
only certain subgroups of patients, e.g., in ER-positive, p53-negative, and HER-2-
negative tumors, which may indicate that the procarcinogenic effect of COX-2 is
not evenly distributed throughout the series. The fact that elevated expression of
COX-2 was associated with poor survival in ER-positive tumors is of particular
interest. Since COX-2-derived PGE2 has been implicated in enhancement of
stromal cell aromatase expression (Zhao et al., 1996), it is possible that elevated
COX-2 expression in ER-positive tumors may enhance a growth-promoting
microenvironment for the tumor cells by inducing estrogen production via the
aromatase pathway in the stromal cells. Consistent with preclinical and clinical
observations that COX-2 can induce aromatase expression and estrogen
biosynthesis, a recent report showed that regular use of aspirin reduced risk for
breast cancer especially in hormone receptor-positive patients (Terry et al., 2004).
In respect to HER-2, it is interesting to note that COX inhibitors enhance the anti-
neoplastic effect of its inhibitors. In a colon carcinoma cell line, the anti-HER-2
monoclonal antibody herceptin and also celecoxib inhibited cell growth in vitro
and in vivo, and the combination of these two drugs was more effective than
either agent alone (Mann et al., 2001). However, a recent clinical phase II study
comprising 12 patients with prior ineffective trastuzumab treatment showed no
clinical response from combining celecoxib with trastuzumab (Dang et al., 2004).
All patients had, however, been heavily pretreated, and their COX-2 expression
status was not determined.
With respect to axillary lymph node status, COX-2 predicted significantly poorer
survival in both node-negative and node-positive groups. This may reflect the
ability of COX-2 to induce metastasis, for example by inducing production and
activation of matrix metalloproteinases (Tsujii et al., 1997; Takahashi et al., 1999).
We wished to address this issue in a clinical setting by detecting COX-2 and
MMP-2 protein expression by immunohistochemistry in tissue microarrays on
consecutively cut sections. This method has certain advantages, since expression
of the two enzymes can be detected in a tissue dot diameter of only 0.6 mm. We
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showed that expression of COX-2 protein was associated with expression of
MMP-2 protein in invasive breast carcinomas. Interestingly, in the group of breast
carcinomas with an expression of COX-2 moderate to high, MMP-2 was elevated
in 56 of 59 (95%) cases. MMP-2-positive cases were, however, not restricted to
COX-2-positive tumors, since MMP-2 was moderate to high in 10 of 133 (77%) of
those cases with low COX-2 immunoreactivity. Elevated expression of COX-2 was
thus associated almost invariably with elevated expression of MMP-2, but COX-2
must not be the only determinant able to modulate expression of MMP-2 in breast
cancer.
Conventional techniques of molecular pathology for analysis of several hundred
specimens require much time and higher costs for material. The tissue microarray
technique allows a simultaneous analysis of up to 150 tissue biopsies from
different tumors on one single tissue chip (Kononen et al., 1998). Furthermore, all
samples are analyzed simultaneously under the same reaction conditions. Zhang
et al. (2003) validated the use of tissue microarray technology by comparing ER,
PR, and HER-2 immunostaining results for 97 breast tumor specimens using
conventional full sections versus tissue microarray sections. Full section versus
tissue microarray concordance was 97% for ER, 98% for PR, and 97% for HER-2,
making tissue microarray equivalent for analysis of routinely used biomarkers of
breast cancer. Furthermore, we have observed in our laboratory that
immunostaining of COX-2 in breast cancer specimens is relatively homogenous,
and we assume that the tissue microarray technique provides representative
results for analysis of immunostaining of COX-2 in breast cancer samples. In
immunohistochemistry, however, quantitation is a challenge. To this end, we
managed to design a relatively simple scoring method producing results highly
concordant between independent evaluators.
In short, our results have provided evidence that COX-2 protein expression is
associated in patients with breast cancer with decreased survival. This result came
from two separate populations. Interestingly, our data indicate that the prognostic
value of COX-2 expression tends to be more marked in certain subgroups of
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patients, e.g., in ER-positive tumors compared to those ER-negative. Thus, the
tumor-promoting effect of COX-2 may be unevenly distributed throughout a
breast cancer population, and that certain subgroups of patients may benefit more
from COX-2 targeted therapy.
COX-2 as a prognostic factor in esophageal carcinoma
Our data indicate that in esophageal adenocarcinoma, elevated expression of
COX-2 is associated with a more aggressive course of the disease and reduced
survival. Furthermore, multivariate analyses suggest that elevated COX-2
expression is an independent prognostic factor for patient survival. In contrast to
esophageal adenocarcinoma, in esophageal squamous cell carcinoma COX-2
expression was not associated with survival. These results suggest that the
prognostic significance of COX-2 depends on the histological type of esophageal
carcinoma. Two recent studies have assessed the connection between COX-2
protein expression and patient outcome in esophageal adenocarcinoma: In
concordance with our finding, in one, patients with high COX-2-expressing
tumors showed poorer survival (France et al., 2004), but the other study found no
such association (Lagorce et al., 2003). In respect to esophageal squamous cell
carcinoma, our results are consistent with those of several other studies finding no
association between COX-2 expression and patients outcome (Shamma et al.,
2000; Kawabe et al., 2002; Kuo et al., 2003).
We detected high expression of COX-2 protein in 79% of the esophageal
adenocarcinomas. Several other studies have reported elevated levels of COX-2 in
Barrett metaplasia, dysplasia, and adenocarcinoma (Wilson et al., 1998; Shirvani
et al., 2000; Lagorce et al., 2003). Similar to our study on esophageal squamous
cell carcinoma, elevated levels of COX-2 mRNA and protein have been reported
(Ratnasinghe et al., 1999; Zimmermann et al., 1999; Shamma et al., 2000;
Kawabe et al., 2002; Kuo et al., 2003; Maaser et al., 2003). Moreover, a
heterogenic intratumoral staining pattern of COX-2 appeared (Maaser et al., 2003;
Shamma et al., 2000), with a significantly higher expression in tumors located in
the distal esophagus than in more proximal areas (Kawabe et al., 2002). In
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esophageal adenocarcinoma, patients with high COX-2-expressing tumors were
more likely to develop distant metastases and local recurrences. In contrast, in
squamous cell carcinoma of the esophagus, COX-2 expression was associated
with none of these clinicopathological variables, in accord with most published
data (Shamma et al., 2000; Kawabe et al., 2002; Kuo et al., 2003). However, one
study did find an association between low expression of COX-2 and advanced
tumor stage and presence of distant metastasis (Kuo et al., 2003).
Interestingly, in patients with esophageal squamous cell carcinoma who
underwent neoadjuvant chemotherapy, low COX-2 expression was associated
with development of distant metastases and reduced overall survival. Our finding
contrast with published findings demonstrating a connection between high COX-2
expression and poor survival of patients on such therapy (Ferrandina et al., 2002;
Kulke et al., 2004a). In these studies, however, the biopsy specimens were
obtained before neoadjuvant treatment, and in our study the specimens were
obtained from surgical resection material after the chemotherapy. Unfortunately,
we were unable to include an analysis of the preoperative biopsy specimens in
this study. In addition, since the COX-2 staining pattern was relatively
heterogeneous in the histological tumor samples, we assume, that staining results
of preoperative biopsies might reflect only sampling artefacts. Several in vitro
studies and one in vivo study show that radiation and chemotherapeutic agents
can enhance expression of COX-2 (Steinauer et al., 2000; Subbaramaiah et al.,
2000; Subbaramaiah et al., 2003; Davis et al., 2004). Although there was no
statistically significant difference in COX-2 expression between the groups with or
without neoadjuvant chemotherapy, we cannot exclude the possibility that COX-
2 expression was induced by the chemotherapy. If this was the case, it can be
hypothesized that COX-2 signals a favorable response to the neoadjuvant
treatment.
Others as well as we have shown a link between COX-2 expression and tumor
necrosis (Wolff et al., 1998; Ristimäki et al., 2001; Bizik et al., 2004) and between
COX-2 expression and p53 overexpression (Subbaramaiah et al., 1999;
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Biramijamal et al., 2001; Leung et al., 2001; Kawabe et al., 2002; Gallo et al.,
2003; Erkinheimo et al., 2004). To address this issue, we evaluated any possible
correlation between COX-2 expression and necrotic area or p53 overexpression
in tumors derived from chemotherapy-treated esophageal squamous cell
carcinoma patients. We found, however, no association between COX-2
expression and tumor necrosis or p53 immunoreactivity. It thus seems that COX-2
expression is independent of the necrotic process and of loss of p53 function in
this series.
In conclusion, our study was the first to report high expression of COX-2 to be
associated with reduced survival in adenocarcinoma of the esophagus. In
contrast, in esophageal squamous cell carcinoma, COX-2 expression was not
associated with patient outcome. However, low COX-2 expression was associated
with poor prognosis in patients with esophageal squamous cell carcinoma who
received neoadjuvant chemotherapy. In summary, our results suggest that the
prognostic significance of COX-2 depends on histological type of esophageal
carcinoma and on treatment applied.
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CONCLUDING REMARKS
Our study shows that overexpression of COX-2 seems to contribute to
tumorigenesis in the breast. Although no conclusions can be drawn from the
association between COX-2 expression and poor outcome in regard to treatment,
the present findings support efforts to initiate clinical trials on the efficacy of COX-
2 inhibitors in adjuvant treatment of breast cancer. Our results also suggest that
COX-2 inhibitors may be more effective in treatment of certain subgroups of
patients. Since COX-2 is overexpressed in HER-2-positive breast cancers, selective
COX-2 inhibitors could be evaluated in this patient group. In addition, our results
provide a basis for study of the predictive value of COX-2 expression in clinical
trials assessing the efficacy of novel aromatase inhibitors versus the classical anti-
estrogen tamoxifen.
Our results show that overexpression of COX-2 also seems to contribute to
tumorigenesis in esophageal adenocarcinoma, but in esophageal squamous cell
carcinoma such a connection is less clear. Unexpectedly, low COX-2 expression
was associated with poor prognosis in patients with esophageal squamous cell
carcinomas who received neoadjuvant chemotherapy, indicating that in
esophageal cancer the prognostic role of COX-2 seems to depend on histological
type and on treatment applied. Differences can be explained by the fact that each
malignancy may have its own pathway of carcinogenesis and its own set of risk
factors and protective exposures. Since esophageal cancers are highly lethal,
current treatment protocols are insufficient, and new treatment modalities are
needed. Research on COX-2 in esophageal cancers offers a new approach to
these patients. However, based on our results, selective COX-2 inhibitors seem
more promising for esophageal adenocarcinoma than for esophageal squamous
cell carcinoma.
In patients with esophageal squamous cell carcinomas who received neoadjuvant
chemotherapy, low COX-2 expression was associated with poor prognosis.
Association of COX-2 with tumor chemoresistance has two potentially important
consequences: First, if this association is evident in pre-treatment biopsy samples,
56
it may serve as a marker predicting chemotherapy treatment failure. Second, use
of COX-2 inhibitors may enhance the effects of therapy. Our study indicates that
even if a combination of COX-2 inhibitors with radio/chemotherapy seems an
interesting approach, this may not be the case for all cancer types. Whether COX-
2 can predict response to chemo- or radiotherapy requires further investigation.
In summary, COX-2 may serve as a biomarker for certain neoplastic conditions.
Alternatively, selective COX-2 inhibitors may prove useful in chemoprevention or
in treatment of breast or esophageal cancers, although recent results showing
increased cardiovascular toxicities among users of COX-2 inhibitors make this
approach less promising. Possible cardiovascular effects will need to be taken into
account in assessment of these drugs’ potential to prevent or treat neoplasias.
57
ACKNOWLEDGEMENTS
The present study was carried out at the Department of Pathology and at the
Molecular and Cancer Biology Research Program, Biomedicum Helsinki,
University of Helsinki during the years 2001-2004. I would like to express my
appreciations to professors Eero Saksela, Leif Andersson, and Veli-Pekka Lehto for
providing excellent research facilities.
I am the most grateful to my supervisor Ari Ristimäki for providing me the study
material and research facilities required. He has been an excellent supervisor
throughout this project and I respect his constant patience and trust in my
research efforts.
Docent Sirpa Leppä and Professor Timo Paavonen, the official reviewers of this
thesis, are gratefully acknowledged for kindly and skillfully reviewing my thesis
manuscript.
My deepest thanks to Caj Haglund for pleasant collaboration. Jan van Lanschot,
Johan Offerhaus, Cristianne Buskens, and Bastiaan van Rees, the collaborators
from Academic Medical Center in Amsterdam, are warmly acknowledged. I also
wish to acknowledge Jorma Isola, Heikki Joensuu, Johan Lundin, and Taina
Turpeenniemi-Hujanen for fruitful collaboration.
I warmly thank all members of our research group in the 5th floor in Biomedicum.
I am the most grateful to Kirsi and Tiina-Liisa for the merry and stimulating
company in the laboratory and outside it. I also thank Kirsi, Mira, Alex, Leena,
and Johanna for a pleasant working atmosphere. This work would not have been
made without the excellent technicians; Tuija in our own laboratory and Elina
and Päivi at the Department of Pathology who are warmly acknowledged for
doing such an excellent and expert job with the immunohistochemistry.
58
My deepest thanks to my parents Pirjo and Erkki and all my grand-parents for
teaching me to appreciate learning and education and for caring and supporting
me at all times. I also owe a depth of gratitude to my parents-in-law Desiree and
Asko for their support and help in our everyday life.
Finally I would like to express my deepest gratitude and love to my husband
Petteri and to our children Laura and Oki for all of their patience, love and
support during these years.
This study was financially supported by grants from the Finnish Cultural
Foundation, the Finnish Cancer Foundation, the Biomedicum Helsinki
Foundation, the Farmos Research Foundation, and the Ida Montini Foundation.
Maikari, March 20th 2005
59
REFERENCES
Abou-Issa,H.M., Alshafie,G.A., Seibert,K., Koki,A.T., Masferrer,J.L. and Harris,R.E. (2001) Dose-
response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary
carcinogenesis. Anticancer Res., 21, 3425-3432.
Ali,S. and Coombes,R.C. (2002) Endocrine-responsive breast cancer and strategies for combating
resistance. Nat.Rev.Cancer., 2, 101-112.
Alshafie,G.A., Abou-Issa,H.M., Seibert,K. and Harris,R.E. (2000) Chemotherapeutic evaluation of
Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol.Rep., 7, 1377-
1381.
Altorki,N.K., Keresztes,R.S., Port,J.L., Libby,D.M., Korst,R.J., Flieder,D.B., Ferrara,C.A.,
Yankelevitz,D.F., Subbaramaiah,K., Pasmantier,M.W. and Dannenberg,A.J. (2003) Celecoxib, a
selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and
carboplatin in early-stage non-small-cell lung cancer. J.Clin.Oncol., 21, 2645-2650.
Amirghahari,N., Harrison,L., Smith,M., Rong,X., Naumann,I., Ampil,F., Shi,R., Glass,J. and
Nathan,C.A. (2003) NS 398 radiosensitizes an HNSCC cell line by possibly inhibiting radiation-
induced expression of COX-2. Int.J.Radiat.Oncol.Biol.Phys., 57, 1405-1412.
Anderson,W.F., Umar,A., Viner,J.L. and Hawk,E.T. (2002) The role of cyclooxygenase inhibitors in
cancer prevention. Curr.Pharm.Des., 8, 1035-1062.
Attiga,F.A., Fernandez,P.M., Weeraratna,A.T., Manyak,M.J. and Patierno,S.R. (2000) Inhibitors of
prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of
matrix metalloproteinases. Cancer Res., 60, 4629-4637.
Baron,J.A. (1995) Aspirin and cancer. Prev.Med., 24, 121-124.
Bennett,A., Charlier,E.M., McDonald,A.M., Simpson,J.S., Stamford,I.F. and Zebro,T. (1977)
Prostaglandins and breast cancer. Lancet, 2, 624-626.
Benoit,V., Relic,B., Leval Xd,X., Chariot,A., Merville,M.P. and Bours,V. (2004) Regulation of HER-
2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene, 23, 1631-1635.
Bilger,A., Shoemaker,A.R., Gould,K.A. and Dove,W.F. (1996) Manipulation of the mouse germline
in the study of Min-induced neoplasia. Semin.Cancer Biol., 7, 249-260.
Biramijamal,F., Allameh,A., Mirbod,P., Groene,H.J., Koomagi,R. and Hollstein,M. (2001) Unusual
profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from
northern Iran. Cancer Res., 61, 3119-3123.
Bizik,J., Kankuri,E., Ristimäki,A., Taieb,A., Vapaatalo,H., Lubitz,W. and Vaheri,A. (2004) Cell-cell
contacts trigger programmed necrosis and induce cyclooxygenase-2 expression. Cell Death Differ.,
11, 183-195.
Boland,G.P., Butt,I.S., Prasad,R., Knox,W.F. and Bundred,N.J. (2004a) COX-2 expression is
associated with an aggressive phenotype in ductal carcinoma in situ. Br.J.Cancer, 90, 423-429.
Boland,G.P., Butt,I.S., Prasad,R., Knox,W.F. and Bundred,N.J. (2004b) COX-2 expression is
associated with an aggressive phenotype in ductal carcinoma in situ. Br.J.Cancer, 90, 423-429.
Boolbol,S.K., Dannenberg,A.J., Chadburn,A., Martucci,C., Guo,X.J., Ramonetti,J.T., Abreu-
Goris,M., Newmark,H.L., Lipkin,M.L., DeCosse,J.J. and Bertagnolli,M.M. (1996) Cyclooxygenase-2
60
overexpression and tumor formation are blocked by sulindac in a murine model of familial
adenomatous polyposis. Cancer Res., 56, 2556-2560.
Bresalier,R.S., Sandler,R.S., Quan,H., Bolognese,J.A., Oxenius,B., Horgan,K., Lines,C., Riddell,R.,
Morton,D., Lanas,A., Konstam,M.A. and Baron,J.A. (2005) Cardiovascular Events Associated with
Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N.Engl.J.Med., .
Brodie,A.M., Lu,Q., Long,B.J., Fulton,A., Chen,T., Macpherson,N., DeJong,P.C.,
Blankenstein,M.A., Nortier,J.W., Slee,P.H., van de Ven,J., van Gorp,J.M., Elbers,J.R.,
Schipper,M.E., Blijham,G.H. and Thijssen,J.H. (2001) Aromatase and COX-2 expression in human
breast cancers. J.Steroid Biochem.Mol.Biol., 79, 41-47.
Brueggemeier,R.W., Quinn,A.L., Parrett,M.L., Joarder,F.S., Harris,R.E. and Robertson,F.M. (1999)
Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens.
Cancer Lett., 140, 27-35.
Buckman,S.Y., Gresham,A., Hale,P., Hruza,G., Anast,J., Masferrer,J. and Pentland,A.P. (1998)
COX-2 expression is induced by UVB exposure in human skin: implications for the development
of skin cancer. Carcinogenesis, 19, 723-729.
Buttar,N.S., Wang,K.K., Anderson,M.A., Dierkhising,R.A., Pacifico,R.J., Krishnadath,K.K. and
Lutzke,L.S. (2002a) The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus
epithelium: an in vitro study. J.Natl.Cancer Inst., 94, 422-429.
Buttar,N.S., Wang,K.K., Leontovich,O., Westcott,J.Y., Pacifico,R.J., Anderson,M.A.,
Krishnadath,K.K., Lutzke,L.S. and Burgart,L.J. (2002b) Chemoprevention of esophageal
adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
Gastroenterology, 122, 1101-1112.
Cameron,A.J., Lomboy,C.T., Pera,M. and Carpenter,H.A. (1995) Adenocarcinoma of the
esophagogastric junction and Barrett's esophagus. Gastroenterology, 109, 1541-1546.
Cameron,A.J. and Romero,Y. (2000) Symptomatic gastro-oesophageal reflux as a risk factor for
oesophageal adenocarcinoma. Gut, 46, 754-755.
Cao,Y., Pearman,A.T., Zimmerman,G.A., McIntyre,T.M. and Prescott,S.M. (2000) Intracellular
unesterified arachidonic acid signals apoptosis. Proc.Natl.Acad.Sci.U.S.A., 97, 11280-11285.
Carlton,P.S., Gopalakrishnan,R., Gupta,A., Liston,B.W., Habib,S., Morse,M.A. and Stoner,G.D.
(2002) Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine-induced tumorigenesis
in the rat esophagus. Cancer Res., 62, 4376-4382.
Castellsague,X., Munoz,N., De Stefani,E., Victora,C.G., Castelletto,R., Rolon,P.A. and
Quintana,M.J. (1999) Independent and joint effects of tobacco smoking and alcohol drinking on
the risk of esophageal cancer in men and women. Int.J.Cancer, 82, 657-664.
Chan,G., Boyle,J.O., Yang,E.K., Zhang,F., Sacks,P.G., Shah,J.P., Edelstein,D., Soslow,R.A.,
Koki,A.T., Woerner,B.M., Masferrer,J.L. and Dannenberg,A.J. (1999) Cyclooxygenase-2 expression
is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 59, 991-994.
Chandrasekharan,N.V., Dai,H., Roos,K.L., Evanson,N.K., Tomsik,J., Elton,T.S. and Simmons,D.L.
(2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other
analgesic/antipyretic drugs: cloning, structure, and expression. Proc.Natl.Acad.Sci.U.S.A., 99,
13926-13931.
Chandrasekharan,N.V. and Simmons,D.L. (2004) The cyclooxygenases. Genome Biol., 5, 241.
61
Chang,S.H., Liu,C.H., Conway,R., Han,D.K., Nithipatikom,K., Trifan,O.C., Lane,T.F. and Hla,T.
(2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast
cancer progression. Proc.Natl.Acad.Sci.U.S.A., 101, 591-596.
Chen,C.N., Sung,C.T., Lin,M.T., Lee,P.H. and Chang,K.J. (2001) Clinicopathologic association of
cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann.Surg., 233,
183-188.
Chow,L.W., Wong,J.L. and Toi,M. (2003) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for
locally advanced breast cancer: preliminary report. J.Steroid Biochem.Mol.Biol., 86, 443-447.
Chow,W.H., Blaser,M.J., Blot,W.J., Gammon,M.D., Vaughan,T.L., Risch,H.A., Perez-Perez,G.I.,
Schoenberg,J.B., Stanford,J.L., Rotterdam,H., West,A.B. and Fraumeni,J.F.,Jr. (1998a) An inverse
relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric
cardia adenocarcinoma. Cancer Res., 58, 588-590.
Chow,W.H., Blot,W.J., Vaughan,T.L., Risch,H.A., Gammon,M.D., Stanford,J.L., Dubrow,R.,
Schoenberg,J.B., Mayne,S.T., Farrow,D.C., Ahsan,H., West,A.B., Rotterdam,H., Niwa,S. and
Fraumeni,J.F.,Jr. (1998b) Body mass index and risk of adenocarcinomas of the esophagus and
gastric cardia. J.Natl.Cancer Inst., 90, 150-155.
Chow,W.H., Finkle,W.D., McLaughlin,J.K., Frankl,H., Ziel,H.K. and Fraumeni,J.F.,Jr. (1995) The
relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus
and gastric cardia. JAMA, 274, 474-477.
Chulada,P.C., Thompson,M.B., Mahler,J.F., Doyle,C.M., Gaul,B.W., Lee,C., Tiano,H.F.,
Morham,S.G., Smithies,O. and Langenbach,R. (2000) Genetic disruption of Ptgs-1, as well as Ptgs-
2, reduces intestinal tumorigenesis in Min mice. Cancer Res., 60, 4705-4708.
Connolly,E.M., Harmey,J.H., O'Grady,T., Foley,D., Roche-Nagle,G., Kay,E. and Bouchier-
Hayes,D.J. (2002) Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an
orthotopic model of breast cancer. Br.J.Cancer, 87, 231-237.
Coogan,P.F., Rao,S.R., Rosenberg,L., Palmer,J.R., Strom,B.L., Zauber,A.G., Stolley,P.D. and
Shapiro,S. (1999) The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast
cancer. Prev.Med., 29, 72-76.
Coogan,P.F., Rosenberg,L., Palmer,J.R., Strom,B.L., Zauber,A.G., Stolley,P.D. and Shapiro,S.
(2000) Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the
large bowel. Cancer Epidemiol.Biomarkers Prev., 9, 119-123.
Corley,D.A., Kerlikowske,K., Verma,R. and Buffler,P. (2003) Protective association of
aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology,
124, 47-56.
Costa,C., Soares,R., Reis-Filho,J.S., Leitao,D., Amendoeira,I. and Schmitt,F.C. (2002) Cyclo-
oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human
breast cancer. J.Clin.Pathol., 55, 429-434.
Crawford,Y.G., Gauthier,M.L., Joubel,A., Mantei,K., Kozakiewicz,K., Afshari,C.A. and Tlsty,T.D.
(2004) Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress
COX-2, promoting a premalignant program. Cancer.Cell., 5, 263-273.
Dang,C.T., D'Andrea,G.M., Moynahan,M.E., Dickler,M.N., Seidman,A.D., Fornier,M.,
Robson,M.E., Theodoulou,M., Lake,D., Currie,V.E., Hurria,A., Panageas,K.S., Norton,L. and
Hudis,C.A. (2004) Phase II study of feasibility of dose-dense FEC followed by alternating weekly
taxanes in high-risk, four or more node-positive breast cancer. Clin.Cancer Res., 10, 5754-5761.
62
Davies,G., Salter,J., Hills,M., Martin,L.A., Sacks,N. and Dowsett,M. (2003) Correlation between
cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin.Cancer Res., 9, 2651-
2656.
Davis,T.W., O'Neal,J.M., Pagel,M.D., Zweifel,B.S., Mehta,P.P., Heuvelman,D.M. and
Masferrer,J.L. (2004) Synergy between celecoxib and radiotherapy results from inhibition of
cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.
Cancer Res., 64, 279-285.
Denkert,C., Winzer,K.J., Muller,B.M., Weichert,W., Pest,S., Kobel,M., Kristiansen,G., Reles,A.,
Siegert,A., Guski,H. and Hauptmann,S. (2003) Elevated expression of cyclooxygenase-2 is a
negative prognostic factor for disease free survival and overall survival in patients with breast
carcinoma. Cancer, 97, 2978-2987.
Devesa,S.S., Blot,W.J. and Fraumeni,J.F.,Jr. (1998) Changing patterns in the incidence of
esophageal and gastric carcinoma in the United States. Cancer, 83, 2049-2053.
DeWitt,D.L. and Smith,W.L. (1988) Primary structure of prostaglandin G/H synthase from sheep
vesicular gland determined from the complementary DNA sequence. Proc.Natl.Acad.Sci.U.S.A.,
85, 1412-1416.
Dixon,D.A., Kaplan,C.D., McIntyre,T.M., Zimmerman,G.A. and Prescott,S.M. (2000) Post-
transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated
region. J.Biol.Chem., 275, 11750-11757.
Dohadwala,M., Batra,R.K., Luo,J., Lin,Y., Krysan,K., Pold,M., Sharma,S. and Dubinett,S.M. (2002)
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates
matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J.Biol.Chem.,
277, 50828-50833.
Dormond,O., Foletti,A., Paroz,C. and Ruegg,C. (2001) NSAIDs inhibit alpha V beta 3 integrin-
mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.
Nat.Med., 7, 1041-1047.
Dubois,R.N., Abramson,S.B., Crofford,L., Gupta,R.A., Simon,L.S., Van De Putte,L.B. and
Lipsky,P.E. (1998) Cyclooxygenase in biology and disease. FASEB J., 12, 1063-1073.
Eberhart,C.E., Coffey,R.J., Radhika,A., Giardiello,F.M., Ferrenbach,S. and DuBois,R.N. (1994) Up-
regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and
adenocarcinomas. Gastroenterology, 107, 1183-1188.
Egan,K.M., Stampfer,M.J., Giovannucci,E., Rosner,B.A. and Colditz,G.A. (1996) Prospective study
of regular aspirin use and the risk of breast cancer. J.Natl.Cancer Inst., 88, 988-993.
Egeblad,M. and Werb,Z. (2002) New functions for the matrix metalloproteinases in cancer
progression. Nat.Rev.Cancer., 2, 161-174.
Erkinheimo,T.L., Lassus,H., Finne,P., van Rees,B.P., Leminen,A., Ylikorkala,O., Haglund,C.,
Butzow,R. and Ristimäki,A. (2004) Elevated cyclooxygenase-2 expression is associated with
altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous
ovarian carcinoma. Clin.Cancer Res., 10, 538-545.
Farrow,D.C., Vaughan,T.L., Hansten,P.D., Stanford,J.L., Risch,H.A., Gammon,M.D., Chow,W.H.,
Dubrow,R., Ahsan,H., Mayne,S.T., Schoenberg,J.B., West,A.B., Rotterdam,H., Fraumeni,J.F.,Jr and
Blot,W.J. (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of
esophageal and gastric cancer. Cancer Epidemiol.Biomarkers Prev., 7, 97-102.
63
Ferrandina,G., Lauriola,L., Distefano,M.G., Zannoni,G.F., Gessi,M., Legge,F., Maggiano,N.,
Mancuso,S., Capelli,A., Scambia,G. and Ranelletti,F.O. (2002) Increased cyclooxygenase-2
expression is associated with chemotherapy resistance and poor survival in cervical cancer
patients. J.Clin.Oncol., 20, 973-981.
Folkman,J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin.Oncol., 29, 15-18.
France,M., Drew,P.A., Dodd,T. and Watson,D.I. (2004) Cyclo-oxygenase-2 expression in
esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy.
Dis.Esophagus, 17, 136-140.
Funk,C.D., Funk,L.B., Kennedy,M.E., Pong,A.S. and Fitzgerald,G.A. (1991) Human
platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene
chromosomal assignment. FASEB J., 5, 2304-2312.
Funkhouser,E.M. and Sharp,G.B. (1995) Aspirin and reduced risk of esophageal carcinoma.
Cancer, 76, 1116-1119.
Gaffney,D.K., Holden,J., Davis,M., Zempolich,K., Murphy,K.J. and Dodson,M. (2001) Elevated
cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix
treated with radiotherapy. Int.J.Radiat.Oncol.Biol.Phys., 49, 1213-1217.
Gallo,O., Schiavone,N., Papucci,L., Sardi,I., Magnelli,L., Franchi,A., Masini,E. and Capaccioli,S.
(2003) Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in
squamous cell carcinoma. Am.J.Pathol., 163, 723-732.
Garcia Rodriguez,L.A. and Gonzalez-Perez,A. (2004) Risk of breast cancer among users of aspirin
and other anti-inflammatory drugs. Br.J.Cancer, 91, 525-529.
Giardiello,F.M., Yang,V.W., Hylind,L.M., Krush,A.J., Petersen,G.M., Trimbath,J.D., Piantadosi,S.,
Garrett,E., Geiman,D.E., Hubbard,W., Offerhaus,G.J. and Hamilton,S.R. (2002) Primary
chemoprevention of familial adenomatous polyposis with sulindac. N.Engl.J.Med., 346, 1054-
1059.
Giovannucci,E., Egan,K.M., Hunter,D.J., Stampfer,M.J., Colditz,G.A., Willett,W.C. and Speizer,F.E.
(1995) Aspirin and the risk of colorectal cancer in women. N.Engl.J.Med., 333, 609-614.
Giovannucci,E., Rimm,E.B., Stampfer,M.J., Colditz,G.A., Ascherio,A. and Willett,W.C. (1994)
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.
Ann.Intern.Med., 121, 241-246.
Goldman,A.P., Williams,C.S., Sheng,H., Lamps,L.W., Williams,V.P., Pairet,M., Morrow,J.D. and
DuBois,R.N. (1998) Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis, 19,
2195-2199.
Gupta,R.A. and Dubois,R.N. (2001) Colorectal cancer prevention and treatment by inhibition of
cyclooxygenase-2. Nat.Rev.Cancer., 1, 11-21.
Gupta,S., Srivastava,M., Ahmad,N., Bostwick,D.G. and Mukhtar,H. (2000) Over-expression of
cyclooxygenase-2 in human prostate adenocarcinoma. Prostate, 42, 73-78.
Half,E., Tang,X.M., Gwyn,K., Sahin,A., Wathen,K. and Sinicrope,F.A. (2002) Cyclooxygenase-2
expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res., 62, 1676-
1681.
64
Han,J.A., Kim,J.I., Ongusaha,P.P., Hwang,D.H., Ballou,L.R., Mahale,A., Aaronson,S.A. and
Lee,S.W. (2002) P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced
apoptosis. EMBO J., 21, 5635-5644.
Hanahan,D. and Weinberg,R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70.
Harris,R.E., Alshafie,G.A., Abou-Issa,H. and Seibert,K. (2000) Chemoprevention of breast cancer in
rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res., 60, 2101-2103.
Harris,R.E., Chlebowski,R.T., Jackson,R.D., Frid,D.J., Ascenseo,J.L., Anderson,G., Loar,A.,
Rodabough,R.J., White,E., McTiernan,A. and Women's Health Initiative. (2003) Breast cancer and
nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative.
Cancer Res., 63, 6096-6101.
Harris,R.E., Kasbari,S. and Farrar,W.B. (1999) Prospective study of nonsteroidal anti-inflammatory
drugs and breast cancer. Oncol.Rep., 6, 71-73.
Harris,R.E., Namboodiri,K., Stellman,S.D. and Wynder,E.L. (1995) Breast cancer and NSAID use:
heterogeneity of effect in a case-control study. Prev.Med., 24, 119-120.
Harris,R.E., Namboodiri,K.K. and Farrar,W.B. (1996) Nonsteroidal antiinflammatory drugs and
breast cancer. Epidemiology, 7, 203-205.
He,T.C., Chan,T.A., Vogelstein,B. and Kinzler,K.W. (1999) PPARdelta is an APC-regulated target of
nonsteroidal anti-inflammatory drugs. Cell, 99, 335-345.
Herschman,H.R. (1996) Prostaglandin synthase 2. Biochim.Biophys.Acta, 1299, 125-140.
Hida,T., Kozaki,K., Ito,H., Miyaishi,O., Tatematsu,Y., Suzuki,T., Matsuo,K., Sugiura,T., Ogawa,M.,
Takahashi,T. and Takahashi,T. (2002) Significant growth inhibition of human lung cancer cells
both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522,
and conventional anticancer agents. Clin.Cancer Res., 8, 2443-2447.
Hida,T., Kozaki,K., Muramatsu,H., Masuda,A., Shimizu,S., Mitsudomi,T., Sugiura,T., Ogawa,M.
and Takahashi,T. (2000) Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity
of various anticancer agents in non-small cell lung cancer cell lines. Clin.Cancer Res., 6, 2006-
2011.
Higuchi,T., Iwama,T., Yoshinaga,K., Toyooka,M., Taketo,M.M. and Sugihara,K. (2003) A
randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective
cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Clin.Cancer Res., 9, 4756-4760.
Hla,T. and Neilson,K. (1992) Human cyclooxygenase-2 cDNA. Proc.Natl.Acad.Sci.U.S.A., 89,
7384-7388.
Howe,L.R., Subbaramaiah,K., Brown,A.M. and Dannenberg,A.J. (2001) Cyclooxygenase-2: a target
for the prevention and treatment of breast cancer. Endocr.Relat.Cancer, 8, 97-114.
Howe,L.R., Subbaramaiah,K., Chung,W.J., Dannenberg,A.J. and Brown,A.M. (1999)
Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial
cells. Cancer Res., 59, 1572-1577.
Howe,L.R., Subbaramaiah,K., Patel,J., Masferrer,J.L., Deora,A., Hudis,C., Thaler,H.T., Muller,W.J.,
Du,B., Brown,A.M. and Dannenberg,A.J. (2002) Celecoxib, a selective cyclooxygenase 2 inhibitor,
protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Cancer Res., 62, 5405-5407.
65
Höyhtyä,M., Fridman,R., Komarek,D., Porter-Jordan,K., Stetler-Stevenson,W.G., Liotta,L.A. and
Liang,C.M. (1994) Immunohistochemical localization of matrix metalloproteinase 2 and its
specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int.J.Cancer, 56, 500-
505.
Hsu,A.L., Ching,T.T., Wang,D.S., Song,X., Rangnekar,V.M. and Chen,C.S. (2000) The
cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human
prostate cancer cells independently of Bcl-2. J.Biol.Chem., 275, 11397-11403.
Huang,M., Stolina,M., Sharma,S., Mao,J.T., Zhu,L., Miller,P.W., Wollman,J., Herschman,H. and
Dubinett,S.M. (1998a) Non-small cell lung cancer cyclooxygenase-2-dependent regulation of
cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-
regulation of interleukin 12 production. Cancer Res., 58, 1208-1216.
Huang,M., Stolina,M., Sharma,S., Mao,J.T., Zhu,L., Miller,P.W., Wollman,J., Herschman,H. and
Dubinett,S.M. (1998b) Non-small cell lung cancer cyclooxygenase-2-dependent regulation of
cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-
regulation of interleukin 12 production. Cancer Res., 58, 1208-1216.
Hwang,D., Scollard,D., Byrne,J. and Levine,E. (1998) Expression of cyclooxygenase-1 and
cyclooxygenase-2 in human breast cancer. J.Natl.Cancer Inst., 90, 455-460.
Hynes,N.E. and Stern,D.F. (1994) The biology of erbB-2/neu/HER-2 and its role in cancer.
Biochim.Biophys.Acta, 1198, 165-184.
Itoh,S., Matsui,K., Furuta,I. and Takano,Y. (2003) Immunohistochemical study on overexpression
of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic
predictor. Oral Oncol., 39, 829-835.
Jacoby,R.F., Seibert,K., Cole,C.E., Kelloff,G. and Lubet,R.A. (2000) The cyclooxygenase-2 inhibitor
celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous
polyposis. Cancer Res., 60, 5040-5044.
Järvinen,T.A., Holli,K., Kuukasjärvi,T. and Isola,J.J. (1998) Predictive value of topoisomerase
IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Br.J.Cancer, 77, 2267-2273.
Jemal,A., Thomas,A., Murray,T. and Thun,M. (2002) Cancer statistics, 2002. CA Cancer.J.Clin., 52,
23-47.
Johnson,T.W., Anderson,K.E., Lazovich,D. and Folsom,A.R. (2002) Association of aspirin and
nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol.Biomarkers Prev.,
11, 1586-1591.
Johnston,S.R. and Dowsett,M. (2003) Aromatase inhibitors for breast cancer: lessons from the
laboratory. Nat.Rev.Cancer., 3, 821-831.
Kargman,S.L., O'Neill,G.P., Vickers,P.J., Evans,J.F., Mancini,J.A. and Jothy,S. (1995) Expression of
prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55, 2556-2559.
Kaur,B.S., Khamnehei,N., Iravani,M., Namburu,S.S., Lin,O. and Triadafilopoulos,G. (2002)
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in
Barrett's esophagus. Gastroenterology, 123, 60-67.
Kaur,B.S., Ouatu-Lascar,R., Omary,M.B. and Triadafilopoulos,G. (2000) Bile salts induce or blunt
cell proliferation in Barrett's esophagus in an acid-dependent fashion.
Am.J.Physiol.Gastrointest.Liver Physiol., 278, G1000-9.
66
Kawabe,A., Shimada,Y., Uchida,S., Maeda,M., Sato,F., Itami,A. and Imamura,M. (2002)
Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic
esophageal squamous cell carcinoma and p53 expression. Oncology, 62, 46-54.
Kawamori,T., Rao,C.V., Seibert,K. and Reddy,B.S. (1998) Chemopreventive activity of celecoxib, a
specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58, 409-412.
Kelley,D.J., Mestre,J.R., Subbaramaiah,K., Sacks,P.G., Schantz,S.P., Tanabe,T., Inoue,H.,
Ramonetti,J.T. and Dannenberg,A.J. (1997) Benzo[a]pyrene up-regulates cyclooxygenase-2 gene
expression in oral epithelial cells. Carcinogenesis, 18, 795-799.
Kelly,L.M., Hill,A.D., Kennedy,S., Connolly,E.M., Ramanath,R., Teh,S., Dijkstra,B., Purcell,R.,
McDermott,E.W. and O'Higgins,N. (2003) Lack of prognostic effect of Cox-2 expression in
primary breast cancer on short-term follow-up. Eur.J.Surg.Oncol., 29, 707-710.
Khuder,S.A. and Mutgi,A.B. (2001) Breast cancer and NSAID use: a meta-analysis. Br.J.Cancer, 84,
1188-1192.
Kiguchi,K., Carbajal,S., Chan,K., Beltran,L., Ruffino,L., Shen,J., Matsumoto,T., Yoshimi,N. and
DiGiovanni,J. (2001) Constitutive expression of ErbB-2 in gallbladder epithelium results in
development of adenocarcinoma. Cancer Res., 61, 6971-6976.
Kim,H.J., Wu,H.G., Park,I.A. and Ha,S.W. (2003) High cyclooxygenase-2 expression is related
with distant metastasis in cervical cancer treated with radiotherapy. Int.J.Radiat.Oncol.Biol.Phys.,
55, 16-20.
Kim,Y.B., Kim,G.E., Cho,N.H., Pyo,H.R., Shim,S.J., Chang,S.K., Park,H.C., Suh,C.O., Park,T.K. and
Kim,B.S. (2002) Overexpression of cyclooxygenase-2 is associated with a poor prognosis in
patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent
chemotherapy. Cancer, 95, 531-539.
Kishi,K., Petersen,S., Petersen,C., Hunter,N., Mason,K., Masferrer,J.L., Tofilon,P.J. and Milas,L.
(2000) Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer
Res., 60, 1326-1331.
Kononen,J., Bubendorf,L., Kallioniemi,A., Bärlund,M., Schraml,P., Leighton,S., Torhorst,J.,
Mihatsch,M.J., Sauter,G. and Kallioniemi,O.P. (1998) Tissue microarrays for high-throughput
molecular profiling of tumor specimens. Nat.Med., 4, 844-847.
Kopp,E. and Ghosh,S. (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science,
265, 956-959.
Kujubu,D.A., Fletcher,B.S., Varnum,B.C., Lim,R.W. and Herschman,H.R. (1991) TIS10, a phorbol
ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin
synthase/cyclooxygenase homologue. J.Biol.Chem., 266, 12866-12872.
Kulke,M.H., Odze,R.D., Mueller,J.D., Wang,H., Redston,M. and Bertagnolli,M.M. (2004a)
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in
patients receiving preoperative chemoradiation for esophageal cancer. J.Thorac.Cardiovasc.Surg.,
127, 1579-1586.
Kulke,M.H., Odze,R.D., Mueller,J.D., Wang,H., Redston,M. and Bertagnolli,M.M. (2004b)
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in
patients receiving preoperative chemoradiation for esophageal cancer. J.Thorac.Cardiovasc.Surg.,
127, 1579-1586.
67
Kundu,N. and Fulton,A.M. (2002) Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control
metastatic disease in a murine model of breast cancer. Cancer Res., 62, 2343-2346.
Kuo,K.T., Chow,K.C., Wu,Y.C., Lin,C.S., Wang,H.W., Li,W.Y. and Wang,L.S. (2003)
Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell
carcinoma. Ann.Thorac.Surg., 76, 909-914.
Kutchera,W., Jones,D.A., Matsunami,N., Groden,J., McIntyre,T.M., Zimmerman,G.A., White,R.L.
and Prescott,S.M. (1996) Prostaglandin H synthase 2 is expressed abnormally in human colon
cancer: evidence for a transcriptional effect. Proc.Natl.Acad.Sci.U.S.A., 93, 4816-4820.
Lagergren,J., Bergstrom,R., Lindgren,A. and Nyren,O. (1999) Symptomatic gastroesophageal reflux
as a risk factor for esophageal adenocarcinoma. N.Engl.J.Med., 340, 825-831.
Lagorce,C., Paraf,F., Vidaud,D., Couvelard,A., Wendum,D., Martin,A. and Flejou,J.F. (2003)
Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated
adenocarcinoma. Histopathology, 42, 457-465.
Lala,P.K., Al-Mutter,N. and Orucevic,A. (1997) Effects of chronic indomethacin therapy on the
development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int.J.Cancer, 73,
371-380.
Langman,M.J., Cheng,K.K., Gilman,E.A. and Lancashire,R.J. (2000) Effect of anti-inflammatory
drugs on overall risk of common cancer: case-control study in general practice research database.
BMJ, 320, 1642-1646.
Langman,M.J., Jensen,D.M., Watson,D.J., Harper,S.E., Zhao,P.L., Quan,H., Bolognese,J.A. and
Simon,T.J. (1999) Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
JAMA, 282, 1929-1933.
Lehmann,J.M., Lenhard,J.M., Oliver,B.B., Ringold,G.M. and Kliewer,S.A. (1997) Peroxisome
proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-
steroidal anti-inflammatory drugs. J.Biol.Chem., 272, 3406-3410.
Leung,W.K., To,K.F., Ng,Y.P., Lee,T.L., Lau,J.Y., Chan,F.K., Ng,E.K., Chung,S.C. and Sung,J.J.
(2001) Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in
gastric cancer. Br.J.Cancer, 84, 335-339.
Li,M., Lotan,R., Levin,B., Tahara,E., Lippman,S.M. and Xu,X.C. (2000) Aspirin induction of
apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol.Biomarkers
Prev., 9, 545-549.
Li,M., Wu,X. and Xu,X.C. (2001a) Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398
through a cytochrome C-dependent pathway in esophageal cancer cells. Int.J.Cancer, 93, 218-
223.
Li,Z., Shimada,Y., Kawabe,A., Sato,F., Maeda,M., Komoto,I., Hong,T., Ding,Y., Kaganoi,J. and
Imamura,M. (2001b) Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal
tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis, 22, 547-551.
Lim,H.Y., Joo,H.J., Choi,J.H., Yi,J.W., Yang,M.S., Cho,D.Y., Kim,H.S., Nam,D.K., Lee,K.B. and
Kim,H.C. (2000) Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.
Clin.Cancer Res., 6, 519-525.
Liotta,L.A., Tryggvason,K., Garbisa,S., Hart,I., Foltz,C.M. and Shafie,S. (1980) Metastatic potential
correlates with enzymatic degradation of basement membrane collagen. Nature, 284, 67-68.
68
Liu,C.H., Chang,S.H., Narko,K., Trifan,O.C., Wu,M.T., Smith,E., Haudenschild,C., Lane,T.F. and
Hla,T. (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in
transgenic mice. J.Biol.Chem., 276, 18563-18569.
Lundin,J., Nordling,S., von Boguslawsky,K., Roberts,P.J. and Haglund,C. (1996) Prognostic value
of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology, 53, 104-
111.
Luong,C., Miller,A., Barnett,J., Chow,J., Ramesha,C. and Browner,M.F. (1996) Flexibility of the
NSAID binding site in the structure of human cyclooxygenase-2. Nat.Struct.Biol., 3, 927-933.
Maaser,K., Daubler,P., Barthel,B., Heine,B., von Lampe,B., Stein,H., Hoffmeister,B., Scherer,H.
and Scherubl,H. (2003) Oesophageal squamous cell neoplasia in head and neck cancer patients:
upregulation of COX-2 during carcinogenesis. Br.J.Cancer, 88, 1217-1222.
Mann,M., Sheng,H., Shao,J., Williams,C.S., Pisacane,P.I., Sliwkowski,M.X. and DuBois,R.N.
(2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma
growth. Gastroenterology, 120, 1713-1719.
Masferrer,J.L., Leahy,K.M., Koki,A.T., Zweifel,B.S., Settle,S.L., Woerner,B.M., Edwards,D.A.,
Flickinger,A.G., Moore,R.J. and Seibert,K. (2000) Antiangiogenic and antitumor activities of
cyclooxygenase-2 inhibitors. Cancer Res., 60, 1306-1311.
Masunaga,R., Kohno,H., Dhar,D.K., Ohno,S., Shibakita,M., Kinugasa,S., Yoshimura,H.,
Tachibana,M., Kubota,H. and Nagasue,N. (2000) Cyclooxygenase-2 expression correlates with
tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin.Cancer
Res., 6, 4064-4068.
Matsumoto,Y., Ishiko,O., Deguchi,M., Nakagawa,E. and Ogita,S. (2001) Cyclooxygenase-2
expression in normal ovaries and epithelial ovarian neoplasms. Int.J.Mol.Med., 8, 31-36.
McCormick,D.L., Madigan,M.J. and Moon,R.C. (1985) Modulation of rat mammary carcinogenesis
by indomethacin. Cancer Res., 45, 1803-1808.
Merlie,J.P., Fagan,D., Mudd,J. and Needleman,P. (1988) Isolation and characterization of the
complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase
(cyclooxygenase). J.Biol.Chem., 263, 3550-3553.
Milas,L., Kishi,K., Hunter,N., Mason,K., Masferrer,J.L. and Tofilon,P.J. (1999) Enhancement of
tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J.Natl.Cancer
Inst., 91, 1501-1504.
Miyamoto,T., Ogino,N., Yamamoto,S. and Hayaishi,O. (1976) Purification of prostaglandin
endoperoxide synthetase from bovine vesicular gland microsomes. J.Biol.Chem., 251, 2629-2636.
Miyata,Y., Koga,S., Kanda,S., Nishikido,M., Hayashi,T. and Kanetake,H. (2003) Expression of
cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis,
angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin.Cancer Res., 9, 1741-
1749.
Morita,I., Schindler,M., Regier,M.K., Otto,J.C., Hori,T., DeWitt,D.L. and Smith,W.L. (1995)
Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J.Biol.Chem.,
270, 10902-10908.
Mukherjee,D., Nissen,S.E. and Topol,E.J. (2001) Risk of cardiovascular events associated with
selective COX-2 inhibitors. JAMA, 286, 954-959.
69
Mutoh,M., Watanabe,K., Kitamura,T., Shoji,Y., Takahashi,M., Kawamori,T., Tani,K.,
Kobayashi,M., Maruyama,T., Kobayashi,K., Ohuchida,S., Sugimoto,Y., Narumiya,S., Sugimura,T.
and Wakabayashi,K. (2002) Involvement of prostaglandin E receptor subtype EP(4) in colon
carcinogenesis. Cancer Res., 62, 28-32.
Nakata,E., Mason,K.A., Hunter,N., Husain,A., Raju,U., Liao,Z., Ang,K.K. and Milas,L. (2004)
Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2
enzyme inhibitors. Int.J.Radiat.Oncol.Biol.Phys., 58, 369-375.
Nakatsugi,S., Ohta,T., Kawamori,T., Mutoh,M., Tanigawa,T., Watanabe,K., Sugie,S., Sugimura,T.
and Wakabayashi,K. (2000) Chemoprevention by nimesulide, a selective cyclooxygenase-2
inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland
carcinogenesis in rats. Jpn.J.Cancer Res., 91, 886-892.
Neugut,A.I., Rosenberg,D.J., Ahsan,H., Jacobson,J.S., Wahid,N., Hagan,M., Rahman,M.I.,
Khan,Z.R., Chen,L., Pablos-Mendez,A. and Shea,S. (1998) Association between coronary heart
disease and cancers of the breast, prostate, and colon. Cancer Epidemiol.Biomarkers Prev., 7, 869-
873.
Nix,P., Lind,M., Greenman,J., Stafford,N. and Cawkwell,L. (2004) Expression of Cox-2 protein in
radioresistant laryngeal cancer. Ann.Oncol., 15, 797-801.
Nussmeier,N.A., Whelton,A.A., Brown,M.T., Langford,R.M., Hoeft,A., Parlow,J.L., Boyce,S.W. and
Verburg,K.M. (2005) Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after
Cardiac Surgery. N.Engl.J.Med., .
O'Connor,J.K., Avent,J., Lee,R.J., Fischbach,J. and Gaffney,D.K. (2004) Cyclooxygenase-2
expression correlates with diminished survival in invasive breast cancer treated with mastectomy
and radiotherapy. Int.J.Radiat.Oncol.Biol.Phys., 58, 1034-1040.
Opitz,O.G., Harada,H., Suliman,Y., Rhoades,B., Sharpless,N.E., Kent,R., Kopelovich,L.,
Nakagawa,H. and Rustgi,A.K. (2002) A mouse model of human oral-esophageal cancer.
J.Clin.Invest., 110, 761-769.
Oshima,M., Dinchuk,J.E., Kargman,S.L., Oshima,H., Hancock,B., Kwong,E., Trzaskos,J.M.,
Evans,J.F. and Taketo,M.M. (1996) Suppression of intestinal polyposis in Apc delta716 knockout
mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
Oshima,M., Murai,N., Kargman,S., Arguello,M., Luk,P., Kwong,E., Taketo,M.M. and Evans,J.F.
(2001) Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific
cyclooxygenase-2 inhibitor. Cancer Res., 61, 1733-1740.
Oshima,M., Oshima,H., Kitagawa,K., Kobayashi,M., Itakura,C. and Taketo,M. (1995) Loss of Apc
heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a
truncated Apc gene. Proc.Natl.Acad.Sci.U.S.A., 92, 4482-4486.
Pai,R., Soreghan,B., Szabo,I.L., Pavelka,M., Baatar,D. and Tarnawski,A.S. (2002) Prostaglandin E2
transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and
gastrointestinal hypertrophy. Nat.Med., 8, 289-293.
Pan,M.R., Chuang,L.Y. and Hung,W.C. (2001) Non-steroidal anti-inflammatory drugs inhibit
matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS
Lett., 508, 365-368.
Parrett,M.L., Harris,R.E., Joarder,F.S., Ross,M.S., Clausen,K.P. and Robertson,F.M. (1997)
Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol.,10, 503-507.
70
Petersen,C., Petersen,S., Milas,L., Lang,F.F. and Tofilon,P.J. (2000) Enhancement of intrinsic tumor
cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin.Cancer Res., 6, 2513-
2520.
Plastaras,J.P., Guengerich,F.P., Nebert,D.W. and Marnett,L.J. (2000) Xenobiotic-metabolizing
cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the
mutagen, malondialdehyde. J.Biol.Chem., 275, 11784-11790.
Pyo,H., Choy,H., Amorino,G.P., Kim,J.S., Cao,Q., Hercules,S.K. and DuBois,R.N. (2001) A
selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo
preferentially on the cells that express cyclooxygenase-2. Clin.Cancer Res., 7, 2998-3005.
Ratnasinghe,D., Daschner,P.J., Anver,M.R., Kasprzak,B.H., Taylor,P.R., Yeh,G.C. and Tangrea,J.A.
(2001) Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against
multidrug resistance possible? Anticancer Res., 21, 2141-2147.
Ratnasinghe,D., Tangrea,J., Roth,M.J., Dawsey,S., Hu,N., Anver,M., Wang,Q.H. and Taylor,P.R.
(1999) Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an
immunohistochemical survey. Anticancer Res., 19, 171-174.
Reddy,B.S., Hirose,Y., Lubet,R., Steele,V., Kelloff,G., Paulson,S., Seibert,K. and Rao,C.V. (2000)
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered
during different stages of carcinogenesis. Cancer Res., 60, 293-297.
Reddy,B.S., Rao,C.V., Rivenson,A. and Kelloff,G. (1993) Inhibitory effect of aspirin on
azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis, 14, 1493-1497.
Ribeiro,U.,Jr, Posner,M.C., Safatle-Ribeiro,A.V. and Reynolds,J.C. (1996) Risk factors for squamous
cell carcinoma of the oesophagus. Br.J.Surg., 83, 1174-1185.
Ristimäki,A., Garfinkel,S., Wessendorf,J., Maciag,T. and Hla,T. (1994) Induction of
cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation.
J.Biol.Chem., 269, 11769-11775.
Ristimäki,A., Honkanen,N., Jänkalä,H., Sipponen,P. and Härkonen,M. (1997) Expression of
cyclooxygenase-2 in human gastric carcinoma. Cancer Res., 57, 1276-1280.
Ristimäki,A., Nieminen,O., Saukkonen,K., Hotakainen,K., Nordling,S. and Haglund,C. (2001)
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder.
Am.J.Pathol., 158, 849-853.
Robertson,F.M., Parrett,M.L., Joarder,F.S., Ross,M., Abou-Issa,H.M., Alshafie,G. and Harris,R.E.
(1998) Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of
rat mammary carcinomas. Cancer Lett., 122, 165-175.
Roche-Nagle,G., Connolly,E.M., Eng,M., Bouchier-Hayes,D.J. and Harmey,J.H. (2004)
Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br.J.Cancer, 91, 359-365.
Rolland,P.H., Martin,P.M., Jacquemier,J., Rolland,A.M. and Toga,M. (1980) Prostaglandin in
human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of
high metastatic potential for neoplastic cells. J.Natl.Cancer Inst., 64, 1061-1070.
Rubio,C.A. (1986) Further studies on the therapeutic effect of indomethacin on esophageal tumors.
Cancer, 58, 1029-1031.
71
Ryu,H.S., Chang,K.H., Yang,H.W., Kim,M.S., Kwon,H.C. and Oh,K.S. (2000) High
cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or
parametrial invasion. Gynecol.Oncol., 76, 320-325.
Sano,H., Kawahito,Y., Wilder,R.L., Hashiramoto,A., Mukai,S., Asai,K., Kimura,S., Kato,H.,
Kondo,M. and Hla,T. (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Cancer Res., 55, 3785-3789.
Saukkonen,K., Nieminen,O., van Rees,B., Vilkki,S., Härkonen,M., Juhola,M., Mecklin,J.P.,
Sipponen,P. and Ristimäki,A. (2001) Expression of cyclooxygenase-2 in dysplasia of the stomach
and in intestinal-type gastric adenocarcinoma. Clin.Cancer Res., 7, 1923-1931.
Schreinemachers,D.M. and Everson,R.B. (1994) Aspirin use and lung, colon, and breast cancer
incidence in a prospective study. Epidemiology, 5, 138-146.
Shamma,A., Yamamoto,H., Doki,Y., Okami,J., Kondo,M., Fujiwara,Y., Yano,M., Inoue,M.,
Matsuura,N., Shiozaki,H. and Monden,M. (2000) Up-regulation of cyclooxygenase-2 in squamous
carcinogenesis of the esophagus. Clin.Cancer Res., 6, 1229-1238.
Sharpe,C.R., Collet,J.P., McNutt,M., Belzile,E., Boivin,J.F. and Hanley,J.A. (2000) Nested case-
control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and
stage. Br.J.Cancer, 83, 112-120.
Sheehan,K.M., Sheahan,K., O'Donoghue,D.P., MacSweeney,F., Conroy,R.M., Fitzgerald,D.J. and
Murray,F.E. (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer.
JAMA, 282, 1254-1257.
Sheng,H., Shao,J. and DuBois,R.N. (2001) Akt/PKB activity is required for Ha-Ras-mediated
transformation of intestinal epithelial cells. J.Biol.Chem., 276, 14498-14504.
Sheng,H., Shao,J., Kirkland,S.C., Isakson,P., Coffey,R.J., Morrow,J., Beauchamp,R.D. and
DuBois,R.N. (1997) Inhibition of human colon cancer cell growth by selective inhibition of
cyclooxygenase-2. J.Clin.Invest., 99, 2254-2259.
Sheng,H., Shao,J., Morrow,J.D., Beauchamp,R.D. and DuBois,R.N. (1998) Modulation of
apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res., 58,
362-366.
Shim,V., Gauthier,M.L., Sudilovsky,D., Mantei,K., Chew,K.L., Moore,D.H., Cha,I., Tlsty,T.D. and
Esserman,L.J. (2003) Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma
in situ and is increased in its normal adjacent epithelium. Cancer Res., 63, 2347-2350.
Shiota,G., Okubo,M., Noumi,T., Noguchi,N., Oyama,K., Takano,Y., Yashima,K., Kishimoto,Y. and
Kawasaki,H. (1999) Cyclooxygenase-2 expression in hepatocellular carcinoma.
Hepatogastroenterology, 46, 407-412.
Shirvani,V.N., Ouatu-Lascar,R., Kaur,B.S., Omary,M.B. and Triadafilopoulos,G. (2000)
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by
bile salts and acid exposure. Gastroenterology, 118, 487-496.
Silva,M.C., Rowlands,M.G., Dowsett,M., Gusterson,B., McKinna,J.A., Fryatt,I. and Coombes,R.C.
(1989) Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res., 49,
2588-2591.
Silverstein,F.E., Faich,G., Goldstein,J.L., Simon,L.S., Pincus,T., Whelton,A., Makuch,R., Eisen,G.,
Agrawal,N.M., Stenson,W.F., Burr,A.M., Zhao,W.W., Kent,J.D., Lefkowith,J.B., Verburg,K.M. and
Geis,G.S. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs
72
for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial.
Celecoxib Long-term Arthritis Safety Study. JAMA, 284, 1247-1255.
Simeone,A.M., Li,Y.J., Broemeling,L.D., Johnson,M.M., Tuna,M. and Tari,A.M. (2004)
Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic
effects in breast cancer cells. Cancer Res., 64, 1224-1228.
Simmons,D.L., Botting,R.M. and Hla,T. (2004) Cyclooxygenase isozymes: the biology of
prostaglandin synthesis and inhibition. Pharmacol.Rev., 56, 387-437.
Simon,L.S., Weaver,A.L., Graham,D.Y., Kivitz,A.J., Lipsky,P.E., Hubbard,R.C., Isakson,P.C.,
Verburg,K.M., Yu,S.S., Zhao,W.W. and Geis,G.S. (1999) Anti-inflammatory and upper
gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA,
282, 1921-1928.
Slamon,D.J., Clark,G.M., Wong,S.G., Levin,W.J., Ullrich,A. and McGuire,W.L. (1987) Human
breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Science, 235, 177-182.
Solomon,S.D., McMurray,J.J., Pfeffer,M.A., Wittes,J., Fowler,R., Finn,P., Anderson,W.F., Zauber,A.,
Hawk,E. and Bertagnolli,M. (2005) Cardiovascular Risk Associated with Celecoxib in a Clinical
Trial for Colorectal Adenoma Prevention. N.Engl.J.Med., .
Sonoshita,M., Takaku,K., Sasaki,N., Sugimoto,Y., Ushikubi,F., Narumiya,S., Oshima,M. and
Taketo,M.M. (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in
Apc(Delta 716) knockout mice. Nat.Med., 7, 1048-1051.
Soslow,R.A., Dannenberg,A.J., Rush,D., Woerner,B.M., Khan,K.N., Masferrer,J. and Koki,A.T.
(2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer, 89,
2637-2645.
Souza,R.F., Shewmake,K., Beer,D.G., Cryer,B. and Spechler,S.J. (2000) Selective inhibition of
cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal
adenocarcinoma cells. Cancer Res., 60, 5767-5772.
Spechler,S.J. and Goyal,R.K. (1996) The columnar-lined esophagus, intestinal metaplasia, and
Norman Barrett. Gastroenterology, 110, 614-621.
Specht,M.C., Tucker,O.N., Hocever,M., Gonzalez,D., Teng,L. and Fahey,T.J.,3rd. (2002)
Cyclooxygenase-2 expression in thyroid nodules. J.Clin.Endocrinol.Metab., 87, 358-363.
Spencer,A.G., Woods,J.W., Arakawa,T., Singer,I.I. and Smith,W.L. (1998) Subcellular localization
of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy.
J.Biol.Chem., 273, 9886-9893.
Spizzo,G., Gastl,G., Wolf,D., Gunsilius,E., Steurer,M., Fong,D., Amberger,A., Margreiter,R. and
Obrist,P. (2003) Correlation of COX-2 and Ep-CAM overexpression in human invasive breast
cancer and its impact on survival. Br.J.Cancer, 88, 574-578.
Steinauer,K.K., Gibbs,I., Ning,S., French,J.N., Armstrong,J. and Knox,S.J. (2000) Radiation induces
upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int.J.Radiat.Oncol.Biol.Phys., 48,
325-328.
Steinbach,G., Lynch,P.M., Phillips,R.K., Wallace,M.H., Hawk,E., Gordon,G.B., Wakabayashi,N.,
Saunders,B., Shen,Y., Fujimura,T., Su,L.K. and Levin,B. (2000) The effect of celecoxib, a
cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N.Engl.J.Med., 342, 1946-1952.
73
Stolina,M., Sharma,S., Lin,Y., Dohadwala,M., Gardner,B., Luo,J., Zhu,L., Kronenberg,M.,
Miller,P.W., Portanova,J., Lee,J.C. and Dubinett,S.M. (2000) Specific inhibition of cyclooxygenase
2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J.Immunol.,
164, 361-370.
Su,J.L., Shih,J.Y., Yen,M.L., Jeng,Y.M., Chang,C.C., Hsieh,C.Y., Wei,L.H., Yang,P.C. and Kuo,M.L.
(2004) Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth
factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer
Res., 64, 554-564.
Su,L.K., Kinzler,K.W., Vogelstein,B., Preisinger,A.C., Moser,A.R., Luongo,C., Gould,K.A. and
Dove,W.F. (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of
the APC gene. Science, 256, 668-670.
Subbaramaiah,K., Altorki,N., Chung,W.J., Mestre,J.R., Sampat,A. and Dannenberg,A.J. (1999)
Inhibition of cyclooxygenase-2 gene expression by p53. J.Biol.Chem., 274, 10911-10915.
Subbaramaiah,K., Hart,J.C., Norton,L. and Dannenberg,A.J. (2000) Microtubule-interfering agents
stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38
mitogen-activated protein kinase pathways. J.Biol.Chem., 275, 14838-14845.
Subbaramaiah,K., Marmo,T.P., Dixon,D.A. and Dannenberg,A.J. (2003) Regulation of
cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and
HuR. J.Biol.Chem., 278, 37637-37647.
Subbaramaiah,K., Norton,L., Gerald,W. and Dannenberg,A.J. (2002) Cyclooxygenase-2 is
overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.
J.Biol.Chem., 277, 18649-18657.
Subbaramaiah,K., Telang,N., Ramonetti,J.T., Araki,R., DeVito,B., Weksler,B.B. and
Dannenberg,A.J. (1996) Transcription of cyclooxygenase-2 is enhanced in transformed mammary
epithelial cells. Cancer Res., 56, 4424-4429.
Swamy,M.V., Herzog,C.R. and Rao,C.V. (2003) Inhibition of COX-2 in colon cancer cell lines by
celecoxib increases the nuclear localization of active p53. Cancer Res., 63, 5239-5242.
Takahashi,Y., Kawahara,F., Noguchi,M., Miwa,K., Sato,H., Seiki,M., Inoue,H., Tanabe,T. and
Yoshimoto,T. (1999) Activation of matrix metalloproteinase-2 in human breast cancer cells
overexpressing cyclooxygenase-1 or -2. FEBS Lett., 460, 145-148.
Talvensaari-Mattila,A., Pääkkö,P. and Turpeenniemi-Hujanen,T. (2003) Matrix metalloproteinase-2
(MMP-2) is associated with survival in breast carcinoma. Br.J.Cancer, 89, 1270-1275.
Tanner,M., Järvinen,P. and Isola,J. (2001) Amplification of HER-2/neu and topoisomerase IIalpha
in primary and metastatic breast cancer. Cancer Res., 61, 5345-5348.
Terakado,N., Shintani,S., Yano,J., Chunnan,L., Mihara,M., Nakashiro,K. and Hamakawa,H. (2004)
Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell
carcinoma. Oral Oncol., 40, 383-389.
Terry,M.B., Gammon,M.D., Zhang,F.F., Tawfik,H., Teitelbaum,S.L., Britton,J.A., Subbaramaiah,K.,
Dannenberg,A.J. and Neugut,A.I. (2004) Association of frequency and duration of aspirin use and
hormone receptor status with breast cancer risk. JAMA, 291, 2433-2440.
Thun,M.J. (1994) Aspirin, NSAIDs, and digestive tract cancers. Cancer Metastasis Rev., 13, 269-
277.
74
Thun,M.J., Namboodiri,M.M., Calle,E.E., Flanders,W.D. and Heath,C.W.,Jr. (1993) Aspirin use and
risk of fatal cancer. Cancer Res., 53, 1322-1327.
Thun,M.J., Namboodiri,M.M. and Heath,C.W.,Jr. (1991) Aspirin use and reduced risk of fatal
colon cancer. N.Engl.J.Med., 325, 1593-1596.
Tomozawa,S., Nagawa,H., Tsuno,N., Hatano,K., Osada,T., Kitayama,J., Sunami,E., Nita,M.E.,
Ishihara,S., Yano,H., Tsuruo,T., Shibata,Y. and Muto,T. (1999) Inhibition of haematogenous
metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br.J.Cancer, 81, 1274-
1279.
Tomozawa,S., Tsuno,N.H., Sunami,E., Hatano,K., Kitayama,J., Osada,T., Saito,S., Tsuruo,T.,
Shibata,Y. and Nagawa,H. (2000) Cyclooxygenase-2 overexpression correlates with tumour
recurrence, especially haematogenous metastasis, of colorectal cancer. Br.J.Cancer, 83, 324-328.
Tong,B.J., Tan,J., Tajeda,L., Das,S.K., Chapman,J.A., DuBois,R.N. and Dey,S.K. (2000) Heightened
expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human
endometrial adenocarcinoma. Neoplasia, 2, 483-490.
Trifan,O.C., Durham,W.F., Salazar,V.S., Horton,J., Levine,B.D., Zweifel,B.S., Davis,T.W. and
Masferrer,J.L. (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and
reduces diarrhea side effect of CPT-11. Cancer Res., 62, 5778-5784.
Tsujii,M. and DuBois,R.N. (1995) Alterations in cellular adhesion and apoptosis in epithelial cells
overexpressing prostaglandin endoperoxide synthase 2. Cell, 83, 493-501.
Tsujii,M., Kawano,S. and DuBois,R.N. (1997) Cyclooxygenase-2 expression in human colon
cancer cells increases metastatic potential. Proc.Natl.Acad.Sci.U.S.A., 94, 3336-3340.
Tsujii,M., Kawano,S., Tsuji,S., Sawaoka,H., Hori,M. and DuBois,R.N. (1998) Cyclooxygenase
regulates angiogenesis induced by colon cancer cells. Cell, 93, 705-716.
Tucker,O.N., Dannenberg,A.J., Yang,E.K., Zhang,F., Teng,L., Daly,J.M., Soslow,R.A.,
Masferrer,J.L., Woerner,B.M., Koki,A.T. and Fahey,T.J.,3rd. (1999) Cyclooxygenase-2 expression is
up-regulated in human pancreatic cancer. Cancer Res., 59, 987-990.
Vadlamudi,R., Mandal,M., Adam,L., Steinbach,G., Mendelsohn,J. and Kumar,R. (1999) Regulation
of cyclooxygenase-2 pathway by HER2 receptor. Oncogene, 18, 305-314.
Vane,J.R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like
drugs. Nat.New Biol., 231, 232-235.
Vona-Davis,L., Riggs,D.R., Jackson,B.J. and McFadden,D.W. (2004) Antiproliferative and
apoptotic effects of rofecoxib on esophageal cancer in vitro(1). J.Surg.Res., 119, 143-148.
Wang,S.C., Lien,H.C., Xia,W., Chen,I.F., Lo,H.W., Wang,Z., Ali-Seyed,M., Lee,D.F.,
Bartholomeusz,G., Ou-Yang,F., Giri,D.K. and Hung,M.C. (2004) Binding at and transactivation of
the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer.Cell., 6, 251-261.
Watanabe,K., Kawamori,T., Nakatsugi,S., Ohta,T., Ohuchida,S., Yamamoto,H., Maruyama,T.,
Kondo,K., Ushikubi,F., Narumiya,S., Sugimura,T. and Wakabayashi,K. (1999) Role of the
prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res., 59, 5093-5096.
Watanabe,O., Shimizu,T., Imamura,H., Kinoshita,J., Utada,Y., Okabe,T., Kimura,K., Hirano,A.,
Yoshimatsu,K., Aiba,M. and Ogawa,K. (2003) Expression of cyclooxygenase-2 in malignant and
benign breast tumors. Anticancer Res., 23, 3215-3221.
75
Wiese,F.W., Thompson,P.A. and Kadlubar,F.F. (2001) Carcinogen substrate specificity of human
COX-1 and COX-2. Carcinogenesis, 22, 5-10.
Williams,C.S., Tsujii,M., Reese,J., Dey,S.K. and DuBois,R.N. (2000a) Host cyclooxygenase-2
modulates carcinoma growth. J.Clin.Invest., 105, 1589-1594.
Williams,C.S., Watson,A.J., Sheng,H., Helou,R., Shao,J. and DuBois,R.N. (2000b) Celecoxib
prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro
and in vivo models. Cancer Res., 60, 6045-6051.
Wilson,K.T., Fu,S., Ramanujam,K.S. and Meltzer,S.J. (1998) Increased expression of inducible
nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated
adenocarcinomas. Cancer Res., 58, 2929-2934.
Wolff,H., Saukkonen,K., Anttila,S., Karjalainen,A., Vainio,H. and Ristimäki,A. (1998) Expression of
cyclooxygenase-2 in human lung carcinoma. Cancer Res., 58, 4997-5001.
Wu,A.W., Gu,J., Ji,J.F., Li,Z.F. and Xu,G.W. (2003) Role of COX-2 in carcinogenesis of colorectal
cancer and its relationship with tumor biological characteristics and patients' prognosis. World
J.Gastroenterol., 9, 1990-1994.
Wulfing,C., Eltze,E., von Struensee,D., Wulfing,P., Hertle,L. and Piechota,H. (2004)
Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after
chemotherapy. Eur.Urol., 45, 46-52.
Wulfing,P., Diallo,R., Muller,C., Wulfing,C., Poremba,C., Heinecke,A., Rody,A., Greb,R.R.,
Bocker,W. and Kiesel,L. (2003) Analysis of cyclooxygenase-2 expression in human breast cancer:
high throughput tissue microarray analysis. J.Cancer Res.Clin.Oncol., 129, 375-382.
Xie,W.L., Chipman,J.G., Robertson,D.L., Erikson,R.L. and Simmons,D.L. (1991) Expression of a
mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing.
Proc.Natl.Acad.Sci.U.S.A., 88, 2692-2696.
Yao,M., Kargman,S., Lam,E.C., Kelly,C.R., Zheng,Y., Luk,P., Kwong,E., Evans,J.F. and Wolfe,M.M.
(2003) Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential
of colorectal carcinoma in mice. Cancer Res., 63, 586-592.
Yokoyama,C., Takai,T. and Tanabe,T. (1988) Primary structure of sheep prostaglandin
endoperoxide synthase deduced from cDNA sequence. FEBS Lett., 231, 347-351.
Zhang,D., Salto-Tellez,M., Putti,T.C., Do,E. and Koay,E.S. (2003) Reliability of tissue microarrays
in detecting protein expression and gene amplification in breast cancer. Mod.Pathol., 16, 79-84.
Zhang,F., Altorki,N.K., Wu,Y.C., Soslow,R.A., Subbaramaiah,K. and Dannenberg,A.J. (2001)
Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for
involvement of bile acids. Gastroenterology, 121, 1391-1399.
Zhang,L., Yu,J., Park,B.H., Kinzler,K.W. and Vogelstein,B. (2000) Role of BAX in the apoptotic
response to anticancer agents. Science, 290, 989-992.
Zhao,Y., Agarwal,V.R., Mendelson,C.R. and Simpson,E.R. (1996) Estrogen biosynthesis proximal to
a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the
CYP19 (aromatase) gene. Endocrinology, 137, 5739-5742.
Zimmermann,K.C., Sarbia,M., Weber,A.A., Borchard,F., Gabbert,H.E. and Schror,K. (1999)
Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res., 59, 198-204.
